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The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase 
that is an integral component of proliferative signaling. When activated by a 
ligand at the plasma membrane, EGFR dimerizes with another ErbB family 
receptor, leading to kinase domain activation and transphosphorylation of C-
terminus tyrosine residues. These phosphotyrosines act as crucial regulators of 
EGFR signaling as effector proteins dock to the receptor at these sites. The 
receptor undergoes clathrin-mediated endocytosis into early endosomes, where 
it can then be trafficked to a lysosome for degradation. However, the kinase 
domain of EGFR retains its activity during trafficking, suggesting that EGFR can 
continue to elicit signaling cascades after internalization. Unfortunately, there is 
no consensus as to how EGFR spatial regulation affects its signaling or 
interaction with downstream effectors. We hypothesize that EGFR localization in 
early endosomes permits unique interactions with downstream effectors. In an 
effort to identify proteins that uniquely associate with the internalized EGFR, we 
have developed a strategy for isolating early endosomes and analyzed the 
protein make-up of these compartments. HeLa cells were stimulated with and 
without EGF, and the post-nuclear supernatant (PNS) was loaded onto a 17%  
vi 
Percoll gradient which separates endosomes based on density. The gradient was 
fractionated, and fractions containing early endosomes were pooled and 
immunoisolated with an EEA1 monoclonal antibody. The morphology of isolated 
compartments was monitored using transmission electron microscopy. 
Endosomes were also subjected to liquid chromatography/tandem mass 
spectrometry (LC-MS/MS) for proteomic analysis. The isolation method 
precipitates early endosome marker proteins, but not marker proteins specific to 
other organelles. Electron microscopy revealed that the isolated vesicles are 
intact and have an average diameter of 68.63 ± 26.74nm. More than 900 proteins 
were isolated with the early endosome, and five proteins were detected in 
endosomes in a ligand-dependent manner: EGFR, RUFY1, STOML2, PTPN23, 
and CCDC51. RNAi was used to knock down RUFY1 and PTPN23 in HeLa cells 
to monitor changes in the trafficking of EGFR. Knock-down studies revealed that 
loss of PTPN23 leads to endocytic accumulation of EGFR and decreased 
degradation of the ligand:receptor complex. Loss of RUFY1 resulted in a 
significant increase in cell growth as well as a resistance to cell death. 
We have developed a rapid and high-throughput isolation technique to 
collect early endosomes from HeLa cells that can be analyzed by LC-MS/MS to 
detect a distinct proteome. The purification protocol yields a highly enriched 
population of early endosomes, as evidenced by immunoblot and LC-MS/MS 
analyses. The isolated vesicles are also intact and exhibit morphology and size 
distribution similar to early endosomes. These data provide evidence that 
endocytic trafficking of the activated EGFR changes the protein composition and  
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A. Epidermal Growth Factor Receptor 
The study of growth factors and their receptors is a rapidly growing field of 
research that began in the 1960s when Stanley Cohen and Rita Levi-Montalcini 
discovered the first growth factors: Nerve Growth Factor (NGF) and Epidermal 
Growth Factor (EGF) [1, 2]. NGF and EGF are small proteins that stimulate the 
growth of nerve and epithelial cells, respectively. Before the discovery of growth 
factors, scientists knew that cells could signal for growth and proliferation, 
particularly during development—but they didn’t understand how this 
phenomenon occurred [1]. The identification of NGF and EGF was pivotal, as 
these proteins could now be studied directly in order to elucidate their functions 
in cellular and organ physiology [3]. These discoveries were a major scientific 
breakthrough that earned Cohen and Levi-Montalcini a shared Nobel Prize in 
1986 [4]. 
 Upon Levi-Montalcini’s discovery of NGF, she and Cohen worked 
diligently to understand its function. Because NGF was discovered in the 
submaxillary glands of mice, they continued using these extracts to study its 
effects on neuronal growth [5]. However, injecting mouse salivary gland extracts 
into newborn pups ended up yielding other, unexpected phenotypes. Cohen 




due to changes in epithelial tissues [2]. During Cohen’s original experiments 
characterizing his novel epithelial tissue-specific growth factor, he referred to the 
protein as the “tooth-lid factor” [2]. While the title was only temporary until he 
coined the name EGF, the “tooth-lid factor” was so named because it directly 
described the effects he saw in mice injected with EGF: it increased the rates of 
tooth growth and eyelid opening in newborn pups [2]. 
 The discovery and characterization of growth factors led to another 
essential discovery—growth factor receptors. Once Cohen had discovered EGF, 
he immediately began working to isolate and identify its receptor. In 1982 Cohen 
successfully isolated and characterized EGF’s cognate receptor from A431 cells 
and mouse livers [3, 6]. In this work, the receptor was identified as a 170kDa 
glycoprotein with intrinsic tyrosine kinase activity. Over the next three decades, 
the EGF-receptor was studied extensively, leading to the most current 
understandings of the signaling, trafficking, regulation, and physiologic 
implications of this protein. 
The epidermal growth factor receptor (EGFR) is a membrane spanning 
receptor tyrosine kinase (RTK) that is an integral component of proliferative 
signaling. Part of the ErbB family of receptors, EGFR is also referred to as ErbB1 
or Her1 (human ErbB1). The other ErbB family members include ErbB2 or Her2, 
ErbB3, and ErbB4. Structurally, EGFR and the ErbB receptors are made up of 
three domains: 1) the extracellular ligand binding domain, 2) the transmembrane 
alpha helices, and 3) the intracellular domain which contains the kinase domain 




domain contains two ligand-binding regions that alternate with two cysteine-rich  
regions. Binding of one of EGFR’s seven endogenous ligands—epidermal growth 
factor (EGF), heparin-binding EGF-like growth factor (HBE), epiregulin (EPR), 
epigen, transforming growth factor alpha (TGFα), amphiregulin (AR), and 
betacellulin (BTC)—to the extracellular region induces a conformational change 
in which the ligand binding regions directly interact with the ligand [7]. This 
structural change exposes the two cysteine-rich domains, allowing the receptor 
to associate with the exposed cysteine-rich domains of another ligand-bound 
EGFR or ErbB family RTK monomer to form a dimer [7].  
The binding of two ligand-bound receptors causes the formation of a 
dimer, which is required for receptor activation [8]. The dimer pair interaction 
structurally induces the activation of the kinase domains. The kinase domain of 
one receptor then phosphorylates the C-terminal tyrosine residues of its dimer 
partner (transphosphorylation) [8]. The cytosolic phosphorylated tyrosine 
residues of the EGFR serve as docking sites for effector molecules that contain 
phosphotyrosine binding (PTB) or src homology 2 (SH2) domains [9]. Proteins 
that dock to the phosphorylated tyrosine residues of an activated EGFR will 
recruit and/or activate other proteins, thus inducing a signaling cascade. For 
example, at the plasma membrane, an activated EGFR dimer will recruit the 
scaffolding proteins Shc and Grb2 to bind to phosphotyrosines and the EGFR 
kinase domains phosphorylate these proteins [9]. Activation of Grb2 leads to the 
recruitment of SOS and induction of the Ras-ERK pathway which is known to 





Figure 1.1 Epidermal Growth Factor Receptor structure. When unbound by a 
ligand, the receptor is often found in a “closed” conformation in which the 
cysteine-rich regions of the extracellular region interact. When a ligand is 
introduced it binds to the two ligand binding domains and a conformational 
change occurs, exposing a cysteine-rich region which can then interact with an 
exposed cysteine-rich region of another ligand-bound ErbB family receptor. 
Red=inactive kinase domain; green=active kinase domain; orange=ligand binding 










pathway which is also known to be involved in the induction of cell proliferation 
via the activation of nuclear transcription factors [9].  
 
B. EGFR Function 
EGFR signaling plays critical roles in cell proliferation, migration, 
differentiation, wound healing, development, and tissue homeostasis. Growth 
factors are mitogens, and the EGFR is an important mitogenic signal transducer. 
In fact, the EGFR is an essential component of cellular physiology and is critical 
for proper tissue development. In 1995, Miettinen et al. produced a line of EGFR 
knockout mice to determine the physiologic importance of the receptor in 
development [10]. They found that their line of knockout (-/-) pups only survived 
for eight days after birth. The mice also had significant developmental 
impairments in multiple epithelial tissues and organs including the lungs, skin, 
and gastrointestinal tract [10]. In 1999 Miettinen also documented that EGFR (-/-) 
pups have compromised craniofacial development (Figure 1.2) [11]. EGFR is 
clearly a crucial component for normal tissue development and homeostasis 
throughout the body. 
While the absence or reduction of EGFR signaling unquestionably causes 
severe developmental impairments, excessive EGFR signaling also has 
detrimental effects. It has been well documented that the receptor is often 
overexpressed and/or over-activated in many different cancer types, including 
non-small cell lung cancer, breast, pancreatic, cervical, head and neck, and 




Figure 1.2 The effects of EGFR knockout on craniofacial development in 
mice. a) A wild-type newborn mouse has a round snout, whereas b) an EGFR (-
/-) mouse has a narrower snout. c) The nostrils of wild-type mice are open 
(arrow), d) but are often closed or narrow (arrow) in EGFR (-/-) mice. e) A wild-
type mouse at four months of age has long whiskers and a well-shaped snout, 
whereas f,g) EGFR (-/-) mice have smaller lower jaws (arrows), deformed eyes, 
and short, curly whiskers. (Used with permission [license # 4332530233617] from 









the first cancer associated with mutated EGFRs. Approximately 70% of GBMs 
express a constitutively active truncation mutant (EGFRvIII) with deletions in 
exons 2-7 of the extracellular domain [18].  The loss of the extracellular domain 
allows spontaneous, ligand-independent receptor dimerization and activation. 
The EGFRvIII mutation is also overexpressed due to gene amplification. In 
addition, constitutively active mutations of the receptor are frequently associated 
with non-small cell lung cancer (NSCLC), one of the most common and lethal 
forms of lung cancer with a 5-year survival rate of only 17% [19, 20]. 
Approximately 50% of NSCLC patients who identify as “never smokers” have 
EGFR exon 19 deletions, exon 20 insertions, and the amino acid point mutation 
L858R [21]. All three of these mutations change the kinase domain of the 
receptor to favor an active state to induce constitutive kinase activity and 
signaling of EGFR.  
In contrast to activating mutations, other cancers seem to be driven by 
EGFR overexpression (e.g. colorectal, breast, pancreatic, and head and neck). 
There are multiple mechanisms by which EGFR levels may be enhanced, 
including increased gene amplification, mRNA production, or protein translation. 
In breast carcinomas, EGFR gene amplification occurs in 6% of tumors, and 91% 
of these tumors also exhibit EGFR protein overexpression [13]. In approximately 
20% of high grade cervical intraepithelial neoplasia (CIN) and invasive cervical 
carcinomas, EGFR gene amplification has also been linked to EGFR 
overexpression and poor prognosis [15]. However, approximately 65% of 




without EGFR-specific gene amplification [14]. For PDAC, these changes in 
protein levels are likely due to overexpression of other ErbB family members 
such as ErbB2 [14] .  
There are currently several FDA-approved anti-EGFR cancer therapies on 
the market. These drugs are generally split up into two classes—monoclonal 
antibodies and kinase inhibitors. The monoclonal antibodies (e.g. Cetuximab) 
target the extracellular portion of the receptor and block the interaction of the 
receptor with extracellular activating ligands. Cetuximab is approved for the 
treatment of cancers that express high levels of EGFR, including colorectal and 
head and neck cancers [22]. Tyrosine kinase inhibitors (TKIs) (e.g. Erlotinib) are 
small molecules that enter the cell and bind (reversibly or irreversibly) to the 
kinase domain of the receptor, blocking effector activation and downstream 
signaling cascades. Erlotinib is approved for use in NSCLC patients whose 
cancers express EGFR kinase activating mutations, including exon 19 deletion 
and exon 21 (L858R) substitution mutations [23]. While these drugs tend to be 
very effective initially for patients whose cancers express over-activated 
receptors, eventually all of these patients will develop resistance to the drugs 
[24]. The exact mechanism by which this resistance occurs is unclear, although 
several studies suggest that the inhibited receptors can form heterodimers with 
other ErbB family members and even the insulin-like growth factor type-1 
receptor (IGF-1R), another RTK with mitogenic effects [25]. In addition to drug 
resistance, patients also tend to develop adverse side-effects to anti-EGFR  




side-effects are skin lesions and conjunctivitis [26, 27]. 
Although significant advances in cell biology research have led to the 
development of targeted therapeutics such as the anti-EGFR cancer drugs, these  
therapies provide an overall survival increase of only a few months for these 
subsets of cancer patients [28]. This lack of improvement, coupled with the 
resistance that develops from these treatments, reveals that there is an 
enormous gap in the field’s understanding of mitogenic signaling. If more robust 
cancer treatments are to be developed, it is essential that the mechanisms 
driving the proliferation and metastasis of these cells are elucidated. Because 
targeting the EGFR directly has yielded only a minimal benefit to patient 
outcomes, it would be prudent to find more specific targets within the receptor’s 
signaling pathways.  
Unfortunately, there are still many facets to EGFR signaling that have yet 
to be elucidated. One such question that could play an important role in 
understanding EGFR downstream signaling is: how does the spatial regulation of 
the receptor affect its signaling? This is the primary question we seek to answer 
in this work.  
 
C. Endocytosis 
The major mechanism through which the EGFR is regulated is the 
endocytic pathway (Figure 1.3). Once the activated dimer is formed it migrates to 
a clathrin-rich region of the plasma membrane where it invaginates and pinches 





Figure 1.3 Endocytic trafficking of the EGFR. The EGFR undergoes ligand-
dependent, clathrin-mediated endocytosis. Early endosomes either mature into 
late endosomes where their contents are transported to lysosomes for 
degradation, or the receptor can be trafficked back to the plasma membrane via 
a recycling endosome. The increasing acidity of these compartments induces 
dissociation of the ligand:receptor complex. The EGFR can continue to elicit 









vesicle fuses with an early endosome [29]. The early endosome, sometimes 
referred to as the signaling or sorting endosome, is the epicenter of endocytic 
trafficking. This organelle is responsible for determining the fate of its contents, 
depending on several factors including what ligand is bound and with which ErbB 
family member the EGFR is dimerized. The early endosome can send proteins 
back to the plasma membrane (recycling) [30], or sequester cargo to be sent to 
and degraded in a lysosome [31]. It has been reported that endocytosis can also 
transport EGFR to the endoplasmic reticulum and the nucleus [32, 33]. Over time 
early endosomes increase in acidity and “mature” into late endosomes [34]. The 
late endosomes will fuse with a lysosome, where the receptor is degraded and 
thus down-regulated. It is important to note that while in the early endosome the 
kinase domain of the receptor remains exposed to the cytosol, allowing the 
receptor to continue interacting with other proteins and downstream effectors 
[35]. 
Until the 1990s, EGFR spatial regulation by the endocytic pathway was 
viewed primarily as a mechanism for downregulating receptor expression after 
activation. Chen et al. discovered in 1989 that an 18 amino acid sequence of the 
EGFR C-terminus is required for both kinase activation and internalization/ 
downregulation of the receptor [36]. Shortly thereafter in 1990, Wells et al. 
discovered that mutated EGFRs that are endocytosis-deficient enhance cell 
transformation [8]. They concluded from this study that without endocytosis, the 
receptor cannot be degraded and thus increases ligand-dependent cell 




EGFR expression. However, in 1994 Bergeron’s group discovered that certain 
EGFR scaffolding proteins involved in Ras signaling (i.e. Shc, Grb2, and mSOS) 
retain their association with active EGFR when it is internalized [30]. Further, in 
1996, Vieira et al. created an endocytosis-defective cell line to study the changes 
in EGFR downstream effector activation after EGF treatment. They found that 
blocking EGFR endocytosis enhanced PLCγ and Shc phosphorylation, but 
decreased ERK1/2, EGFR, & PI3K phosphorylation [31]. These works, among 
others, pushed the field of EGFR trafficking toward a new line of thinking: 
endocytosis can positively and negatively affect receptor:effector communication. 
However, there is currently no consensus on how these changes occur, or how 
they contribute to EGFR signaling and overall cellular physiology. 
It has been well established that the endocytic pathway is important in the 
spatial as well as temporal regulation of the EGFR. The receptor is regulated 
temporally by the amount of time it takes to traverse the entire endocytic 
pathway, and how long the receptor is sequestered at each point of the pathway. 
About 10% of a cell’s inactive EGFRs are constitutively recycled into early 
endosomes and back to the plasma membrane [37]. It has also been shown that 
different ligands induce varied endocytic responses. For example, it is known that 
TGFα triggers rapid recycling of the receptors, while EGF triggers the receptor to 
be maintained in early endosomes, leading to its eventual degradation and 
downregulation [38].  
One explanation for these distinct differences in ligand:receptor trafficking 




relatively high affinity for binding EGFR of 0.42nM [39], and thus does not 
dissociate from the receptor in the acidic environment of early endosomes (pH 
6). However, TGFα has a slightly lower affinity for the receptor at 11.9nM [39], 
causing the ligand:receptor complex to dissociate in early endosomes, permitting 
receptor recycling to the plasma membrane [38]. Though both ligands are 
considered to have “high” affinities for EGFR [40], they do not have the same 
effects on receptor trafficking. Conversely, the work of Moriai et al. suggests that 
EGF and TGFα have similar affinities for EGFR, and that certain mutations in the 
ligand binding domain of some EGFRs may contribute to the different binding 
affinities and downstream signaling effects of ligands [41]. 
 The endocytic pathway is a complex and dynamic system made up of 
various organelles [42]. Endocytosis is a fundamental cellular process in which 
extracellular nutrients and portions of the plasma membrane are internalized into 
the cell [42]. A section of plasma membrane will invaginate and pinch off to form 
an intracellular vesicle [42]. These preliminary vesicles are typically formed with 
the assistance of several adaptor and scaffolding proteins that are found near or 
on the plasma membrane [43]. For example, clathrin-mediated endocytosis 
(CME) requires the cytosolic protein clathrin, which forms a triskelion coat around 
the portion of plasma membrane that is to be internalized [43]. This process also 
requires another protein called dynamin that plays a critical role in the scission of 
the new vesicle from the plasma membrane [43]. CME is also referred to as 
receptor-mediated endocytosis, as it occurs when a plasma-membrane receptor 




(e.g. EGF binding to EGFR) [43]. During CME, after the new vesicle is created 
the clathrin coat is shed. This intermediate vesicle is then trafficked to and fused 
with an endosome, of which there are several types [43]. The destination of each 
vesicle is specific to its cargo and has a direct impact on the fate of that cargo. 
This process is highly regulated by actin filaments and microtubules, adaptor 
proteins, and GTPases such as the RAB proteins [43]. The RAB family of 
proteins are Ras-like GTPases that play an essential role in the endocytic 
pathway by recruiting effectors that induce the formation and motility of 
endosomes [44]. There are more than 60 different RAB proteins, and each one is 
generally specific to a distinct cellular compartment [45]. In 1990, Chavrier and 
Zerial determined that RAB5 is specific to the plasma membrane and early 
endosomes, and RAB7 localizes to late endosomes [46]. RAB11 is another 
member of the RAB family that is specifically localized to recycling endosomes 
[47]. These three RAB proteins are the major players involved in generating the 
vesicles involved in the early phases of endocytosis (i.e. early, late, and recycling 
endosomes). 
 Clathrin-mediated endocytosis is the primary pathway by which activated 
EGFR enters early endosomes when stimulated with low, endogenous 
concentrations of ligand (i.e. ~1ng/mL or 0.16nM EGF) [48]. However, there are 
other types of endocytosis that utilize adapter proteins similar to clathrin. For 
example, caveolae are small pits in the plasma membrane made up of lipid rafts 
and the protein caveolin [49]. Caveolae are also involved in the endocytosis of 




to CME, as it also requires dynamin for the scission and formation of vesicles 
[43]. It also differs from CME in that caveolae cargo can either be delivered to 
early endosomes or to caveosomes [49]. Caveosomes are pH-neutral 
intracellular vesicles that strictly contain cargo transported from caveolae, and 
they do not contain early endosome proteins, although their function is similar to 
early endosomes [49]. There are other routes of endocytosis that do not involve 
clathrin or caveolae, which are collectively termed clathrin- and caveolae-
independent endocytosis [43]. The major routes of EGFR-endocytosis are CME 
at low ligand concentrations, and caveolae-mediated endocytosis (CavME) at 
high ligand concentrations (i.e. >10ng/mL or >1.6nM EGF) [48].  
 Whether via CME or CavME, most endocytic cargo will be transported into 
early endosomes. Early endosomes are so named because they are found in the 
cytosol near the plasma membrane, and they are the first major constituent 
within the endocytic pathway. These organelles are considered to be slightly 
acidic, with a pH of ~6.0 and a density of 1.035-1.042g/mL [34, 50]. Early 
endosomes are the first pit-stop in the pathway, and the sequestration of 
receptors here is critical to their ultimate fate.  
There are two distinct populations of early endosomes: dynamic and 
static. In 2006 Lakadamyali and Rust discovered and characterized these types 
of endosomes by their mobility and maturation kinetics [51].  To do this, RAB5 
and RAB7 were fluorescently tagged and the association of these proteins with 
various ligands that undergo CME were tracked using live cell imaging. They 




they mature very slowly. The dynamic early endosomes are strongly associated 
with microtubules and mature rapidly into late endosomes. Remarkably, 
ligand:receptor complexes that are normally degraded via the endocytic pathway, 
such as EGF:EGFR and low density lipoprotein and its cognate receptor 
(LDL:LDLR), were preferentially trafficked into the dynamic population of early 
endosomes. On the other hand, complexes that are typically recycled, such as 
transferrin and its receptor (Tfn:TfnR), were trafficked non-specifically to both 
populations of early endosomes [51]. This study provides further evidence that 
the endocytic pathway is highly regulated and the fate of every cargo that enters 
is tightly monitored.  
 As evidenced by the fates of the EGFR and TfnR, early endosomal 
contents can be segregated into various legs of the endocytic pathway. Certain 
proteins that are marked for recycling back to the plasma membrane can be sent 
directly to the cell membrane by an intermediate vesicle, or trafficked to a larger 
specialized vesicle called the recycling endosome [42]. Contents that are not 
recycled will remain sequestered in early endosomes. The organelles that 
comprise the endocytic pathway possess proton pumps on their membranes that 
maintain their luminal pH [34, 52]. However, over time these pumps will increase 
the acidity of early endosomes. This is a crucial step in the “maturation” process 
of an early endosome into a late endosome [53].  
Late endosomes are also termed “multivesicular bodies” or MVBs, and 
have an acidic pH of ~5.3 and a density of 1.048-1.070g/mL [34, 50]. The name 




the organelle [54]. These are small, membrane-bound vesicles that are 
internalized from the outer membrane of the late endosome itself, which is also 
referred to as the “limiting membrane” [54]. Receptors and other cargo found in 
the late endosome that are to be degraded are marked as such by entering into 
these intraluminal vesicles [54]. There are specific protein complexes called 
ESCRTs (endosomal sorting complex required for transport) that are required for 
the transport of cargo from the limiting membrane into intraluminal vesicles of 
late endosomes [55]. ESCRT complexes specifically interact with ubiquitinated 
cargo within the late endosome, as ubiquitination marks proteins for degradation 
[55]. Once a cargo is sequestered into an intraluminal vesicle, it is destined to be 
transported to a lysosome where it will be degraded. The late endosome will 
temporarily fuse with a lysosome and transfer its contents (intraluminal vesicles) 
to the lysosome [56].  
Lysosomes are separate organelles that have a pH of ~5.0 and a density 
of between 1.070-1.110g/mL [34, 50]. The sole purpose of a lysosome is to 
degrade proteins, as they are filled with acid hydrolases to break down cargo 
[56]. This compartment is the final stop in the endocytosis of cargo that is marked 
for degradation (i.e. ubiquitinated). This degradation process is essential for the 
down-regulation of a multitude of cellular components, including signaling 
receptors like EGFR [56].  
 
D. Significance and Statement of Specific Aims 




hyperactivated in multiple cancer types (e.g. breast, colon, lung, pancreatic, etc.). 
While there are currently several FDA-approved therapies that target EGFR in 
these cancers, in many cases these cancers either do not respond or quickly 
develop resistance [24]. Further, patients who do benefit from anti-EGFR 
therapies only gain a few additional months of life. As a result, it is clear that 
targeting EGFR directly is not the most effective way to mitigate its signaling in 
cancer. We propose that better alternative approaches for disrupting EGFR 
signaling will come from examining the molecular mechanisms that regulate 
EGFR activity, i.e. endocytosis. It has been well understood for decades that 
endocytic spatial regulation plays a major role in receptor expression and 
downregulation. However, in recent years it has been discovered that receptor 
endocytosis also plays a role in downstream effector activity. How this process 
specifically affects overall EGFR signaling is not completely understood, and it 
could be a useful target for disrupting hyperactivated signaling. 
My research goal was to understand how endocytosis affects EGFR signal 
transduction, and to use this information to discover new targets for cancer 
therapies. The objective of this work was to determine the effects of EGFR 
spatial regulation on its signaling. My central hypothesis was that the spatial 
regulation of EGFR permits specific effector interactions that directly influence 
downstream signaling. This hypothesis was based on the most recent data in the 
field which suggest that endocytic trafficking of EGFR induces changes in 
downstream effector activation. For example, blocking EGFR endocytosis 




recently, the work of Galperin and Sorkin suggests that MEK enters endosomes 
and acts as a negative regulator of MAPK signaling upon EGF stimulation [57]. 
While the spatial regulation of EGFR clearly plays a role in effector activity, there 
is controversy within the field surrounding endosome-specific effectors and their 
implications on overall signal transduction. The rationale for this work was that a 
comprehensive understanding of the effects of EGFR:effector interactions within 
endosomes will be a means for discovering many new drug targets for altering 
EGFR mitogenic signaling. Considering the current outcomes for EGFR targeting 
in cancer, this information is critical for the discovery of more effective 
treatments. 
My hypothesis was tested with the following aims:  
Aim 1: Identify and characterize key effectors within early endosomes.  
Aim 1a. Develop a non-invasive strategy to purify early endosomes. 
In order to achieve a global, comprehensive picture of the early endosome 
effector population, we isolated intact early endosomes from cultured cell lines. 
Aim 1b. Characterize effector activation in early endosomes. 
We used mass spectrometry to characterize early endosome-specific effectors 
following treatment with and without EGF. The goal of this sub-aim was to 
determine which effectors are constitutively present in the early endosome, and 
which effectors are selectively localized to early endosomes by EGFR membrane 
trafficking.  
Aim 2: Determine the physiologic effects of endocytic spatial regulation on  




Based on my hypothesis, we determined how the spatial regulation of EGFR 
influences cell physiology using cultured cell lines. We used assays to measure 
cell growth and viability to determine how these processes are affected by the 
absence of specific downstream effectors of EGFR. 
The aim of this work was to provide a systematic and comprehensive 
approach to understanding how EGFR signaling is regulated, which will lead to 
discovering new ways to attenuate it more effectively. The work proposed in Aim 
1 gave us a more complete picture of early endosome-specific effectors. More 
specifically, we discovered that the proteins RUFY1, PTPN23, STOML2, and 
CCDC51 associate with early endosomes in an EGF-dependent manner. The 
work proposed in Aim 2 helped us identify what roles the proteins discovered in 
Aim 1 play in the endocytic trafficking of EGFR. This work has been published in 
the Journal of Biological Chemistry. Additional work has been done to 
characterize how the loss of RUFY1 and PTPN23 affects cell number and 







MATERIALS AND METHODS 
A. Cell Lines—HeLa cells were acquired from American Type Culture 
Collection (ATCC). Cells were cultured at 37°C in 5% CO2 and maintained in 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 5% Fetal 
Bovine Serum (FBS, Invitrogen), 100 units/mL streptomycin, 100 units/mL 
penicillin, and 2mM glutamine [58]. 
B.  Post-Nuclear Supernatant Preparation—Cells were grown to confluence in 
15cm dishes, serum starved for 2 hours at 37°C, then incubated with or without 
10ng/mL EGF ligand (ProSpec, #cyt-217-a) for 15 minutes immediately prior to 
harvest. Cell lysates were prepared by washing twice with room temperature 
(RT) PBS and equilibrating to 4°C on ice, followed by equilibrating in ice-cold 
lysis buffer (TES-10mM triethanolamine, 1mM EDTA, 0.25M sucrose pH 7.2). 
Cells were incubated on ice with TES buffer (supplemented with 2mM PMSF, 
1mM Na3VO4, 10μM pepstatin, and 1μM aprotinin) until cells began to swell, but 
before bursting (approximately 5 minutes), and scraped with a rubber policeman. 
The collected cells were pipetted up and down 40 times with a P1000 pipetman 
and centrifuged at 200 x g for 10 minutes at 4°C in a tabletop centrifuge to create 
a post-nuclear supernatant (PNS) which was subsequently collected. The pellet 
was resuspended in TES buffer and centrifuged a second time at 200 x g for 10 






C.  Percoll Gradient Fractionation−Twenty-four hours prior to experimentation, 
stock Percoll (GE Healthcare) was equilibrated with 2.5M sucrose at a ratio of 
9:1. The 90% Percoll/0.25M sucrose solution was stored at 4°C until use. 
Samples were prepared as indicated (by PNS preparation via either osmotic lysis 
or mechanical lysis, or by sucrose gradient fractionation), and each sample was 
mixed with the 90% Percoll solution (final concentration 17% Percoll) and TES to 
a total volume of 11.5mL. Buffers were supplemented with 2mM PMSF, 1mM 
Na3VO4, 10μM pepstatin, and 1μM aprotinin before use. PNS/Percoll/Buffer 
mixtures were pipetted into 16mm x 67mm OptiSeal™ polypropylene tubes 
(Beckman Coulter) and loaded into a pre-chilled VTi65.1 vertical rotor. Density 
beads (with known densities in 17% Percoll/250mM sucrose) (GE Healthcare) 
were loaded into a separate tube containing 17% isotonic Percoll in buffer and 
mixed. Samples were spun in a Beckman Coulter Optima L-100 XP 
Ultracentrifuge at 50,000 x g for 25 minutes with max acceleration and brake. 
Samples were then fractionated from the bottom of the centrifuge tube in 10-drop 
aliquots (~330μL) into pre-chilled Eppendorf tubes (~30 fractions per gradient) 
using a peristaltic pump and a glass pipet at 4°C [50]. For experiments where 
fractions were subjected to affinity purification, the fractions in which EEA1 
protein concentration peaked were pooled together (~6 fractions per condition, 
~2mL total) and mixed by inverting and gently pipetting up and down. For 
experiments where fractions were not pooled but analyzed directly via 
immunoblot, each fraction was diluted in 6X SDS sample buffer containing 10% 






21,000 x g to pellet Percoll. The tube containing density beads was imaged and 
Rf values were calculated based on bead migration in the gradient.  
D.  Affinity Purification of Early Endosomes—Approximately 0.44μg of EEA1 
monoclonal antibody (Cell Signaling, #3288) was pre-conjugated to ~2mL of 
pooled EEA1 peak fractions (Rf of ~0.25-0.10) from Percoll gradient samples 
overnight at 4°C with rotation. Protein G Dynabeads (Invitrogen) were washed 
three times in PBS before use and ~4.0 x 107 Dynabeads were incubated with 
each antibody-conjugated sample and rotated at 4°C for 1 hour. Magnetic beads 
were isolated and the first supernatant (pass through) was collected. The beads 
were then washed three times in ice-cold PBS and eluted in 6X SDS buffer 
containing 10% βME and boiled at 100°C for 3 minutes. Remaining samples 
collected were diluted in 6X SDS buffer with 10% βME and boiled. Any samples 
containing Percoll were centrifuged at 21,000 x g to pellet Percoll. 
E. Immunoblotting—Samples were loaded as a percentage of total sample 
volume, resolved by SDS-PAGE, and transferred to nitrocellulose. Membranes 
were probed with the following antibodies according to manufacturer’s directions: 
EGFR (Santa Cruz, #sc-03), TfnR (BD Biosciences, #612124), LAMP2 
(University of Iowa Hybridoma Bank, #H4B4), EEA1 (BD Biosciences, #610456), 
Na/K-ATPase (Sigma, #A276-only used where indicated), Na/K-ATPase (Cell 
Signaling, #3010), Calnexin (Assay Designs, #SPA-850), pY1068 (Cell Signaling, 
#2236), PTPN23 (Proteintech, #A304-883A), RUFY1 (ThermoFisher Scientific, 
#PA5-31400), STOML2 (Abcam, #ab191884), α-tubulin (Sigma-Aldrich, #T6199), 






horseradish peroxidase conjugated secondary antibody (anti-mouse or anti-
rabbit, Thermo Fisher-Pierce), immunoreactive proteins were subjected to 
Enhanced Chemiluminescence and visualized using a Fotodyne imaging system. 
Western blots were quantified using Image J software. 
F.  Indirect Immunofluorescence—HeLa cells were grown to confluency on 
NaOH treated, sterile 12mm round glass coverslips. Serum starved cells were 
incubated with EGF (ProSpec, #cyt-217-a) ligand for the indicated amount of 
time. Cells were stimulated with 10ng/mL fluorescent Alexa-647-EGF ligand 
(Invitrogen) for 10 min and pulse-chased following previously described methods 
[59]. After EGF stimulation, cells were subjected to indirect immunofluorescence 
as described previously [60] using EGFR (Ab-1, EMD Millipore, #GR01), EEA1 
(BD Biosciences, #610456), PTPN23 (Proteintech, #A304-883A), RUFY1 
(ThermoFisher Scientific, #PA5-31400), and STOML2 (Abcam, #ab191884) 
primary antibodies prepared by manufacturer recommended dilutions. 
Immunoreactive proteins were visualized using goat anti-rabbit Alexa488- and 
goat anti-mouse Alexa568-labeled secondary antibodies (Life Technologies), 
respectively. Coverslips were mounted onto glass slides with Prolong Gold 
Antifade (Life Technologies) [60]. Slides were cured in the dark overnight before 
imaging. Images were taken in the middle plane of the cells using a 60X oil 
immersion objective lens on a Nikon A1R confocal microscope. 
G.  Colocalization Analysis—Colocalization of EGF or EGFR with EEA1 was 
quantified as described by Lopez-Alcala et al. (50) and Vanlandingham et al. 






Colocalization plug-in (Pierre Bourdoncle, Institut Jacques Monod, Service 
Imagerie, Paris) to generate a binary image of colocalized pixels from two 
separate channels. ImageJ was used to automate channel thresholding, and 
colocalization was established for pixels whose intensities were higher than 
threshold and for which the ratio of intensity was greater than 50%. The data 
were plotted as the ratio of the integrated intensity from the two images. All data 
represent the average of three independent experiments, with a total of ~300 
cells measured per experiment. 
H.  Coomassie Staining—Immunoprecipitated early endosomes were 
resolved on a 12% SDS-PAGE. The gel was rinsed once in ddH2O and covered 
with Coomassie (50% MeOH, 0.05% Coomassie Brilliant Blue R [Sigma], 10% 
acetic acid, 40% ddH2O) and microwaved for 5 seconds. The gel was incubated 
with Coomassie at RT with gentle rocking for 15 minutes. The Coomassie was 
removed and the gel was rinsed twice in ddH2O. The gel was then covered in 
destain solution (7% glacial acetic acid, 5% MeOH, 88% ddH2O) and incubated 
overnight at RT with gentle rocking. The gel was rinsed in ddH2O, imaged using 
a Fotodyne imaging system, and stored in 7% acetic acid/ddH2O at 4°C.  
I. In-Gel Protein Digestion—This protocol is modified from Jensen et al. [61]. 
A Coomassie stained SDS-PAGE gel was cut into 1mm3 plugs and incubated in 
100mM triethylammonium bicarbonate (TEA-BC, Sigma) at RT for 15 minutes. 
Acetonitrile (ACN) was added to the TEA-BC solution and the gel plugs were 
incubated at RT for 15 minutes with gentle vortexing. The solvent was removed 






longer visible. Solvent was removed and the gel plugs were dried in a SpeedVac 
for 5 minutes. The dried plugs were incubated in dithiothreitol (DTT) (20mM DTT 
[BioRad],100mM TEA-BC) at 56°C for 45 minutes, followed by iodoacetamide 
(55mM iodoacetamide [Sigma], 100mM TEA-BC) at RT for 30 minutes protected 
from light. Iodoacetamide was removed and gels were washed in 50mM TEA-BC 
at RT for 15 minutes, followed by the addition of ACN for 15 minutes at RT with 
gentle vortexing. The gel plugs were again dried for 5 minutes in a SpeedVac, 
and incubated in digestion buffer (20ng/μL modified Trypsin [Promega] in 50mM 
TEA-BC) for approximately 10 minutes until the gel plugs swelled. After swelling, 
50mM TEA-BC was added to the plugs, followed by 37°C overnight incubation in 
a shaker. Digestion supernatants from the upper and lower half of the gel were 
combined for each sample. 
J. Extraction of Peptides—This protocol is modified from Shevchenko, et al. 
[62]. LC-MS grade water was added to the digested gel plugs to give a final 
concentration of 25mM TEA-BC. Two volumes of 1:2 5% v/v formic 
acid:acetonitrile was added and incubated at RT for 15 minutes in a shaker 
(100rpm in a C25 Incubator Shaker [New Brunswick Scientific]). Liquid 
surrounding the gel pieces was transferred to a clean microtube and dissolved in 
Chromatography Buffer A (2% v/v acetonitrile/0.1% v/v formic acid). The 
dissolved sample was filtered through a 0.45μm regenerated cellulose syringe 
filter (Thermo #F2504-7) to remove any remaining gel material. Resolubilized gel 
band digests were desalted and concentrated using C18 PROTO™, 300 Å Ultra 






were cooled to -80°C, dried using a SpeedVac, and redissolved in 
Chromatography Buffer A. Sample absorbance was read at 205nm using a 
NanoDrop 2000 spectrophotometer to determine peptide concentration. Sample 
volumes were adjusted in Buffer A to normalize peptide concentrations to 
0.1μg/μL. 
K. Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)—Gel 
band digests (0.5µg) were separated on 12cm of Aeris Peptide XB-C18, 3.6μm, 
100Å material (Phenomenex, Torrance, CA, USA) packed into a 360µm OD x 
100µm ID fused silica tip that was pulled using a Model P-2000 Micropipette 
Puller (Sutter Instrument Co., Novato, CA, USA). Peptides were eluted from the 
column using an EASY n-LC UHPLC system (Thermo Fisher Scientific, Waltham, 
MA, USA) in an 80 minute linear gradient using Buffer A and Buffer B (80% v/v 
acetonitrile/0.1% v/v formic acid) as mobile phases (from 0% Buffer B to 50% 
Buffer B). The samples were then separated by a 5 minute linear gradient from 
50% Buffer B to 95% Buffer B, followed by a 5 minute wash in 95% Buffer B. The 
sample was introduced into the LTQ-Orbitrap Elite (ThermoElectron) mass 
spectrometer by nanoelectrospray using a Nanospray Flex source 
(ThermoElectron). The ion transfer capillary temperature was set to 225°C and 
the spray voltage was set to 1.6kV. An Nth Order Double Play was created in 
Xcalibur v2.2. Scan event one of the method obtained an FTMS MS1 scan 
(normal mass range; 240,000 resolution, full scan type, positive polarity, profile 
data type) for the range 300-2000m/z. Scan event two obtained ITMS MS2 scans 






that had a minimum signal threshold of 5,000 counts from scan event one. The 
lock mass option was enabled (0% lock mass abundance) using the 
371.101236m/z polysiloxane peak as an internal calibrant. Proteome Discoverer 
v1.4.1.14 (Thermo Fisher Scientific) was used to analyze the mass spectrometer 
data. MS2 scan data were extracted from the Xcalibur RAW file, CID MS2 scans 
were searched in Mascot v2.5.1 (Matrix Science, Inc., Boston, MA, USA) and 
SequestHT, and results were collected in a single file. The protein database 
UniprotKB Homo sapiens version 3/9/2016 reference proteome canonical and 
isoform sequences, with cRAP database (thegpm.org) version 1/1/2012 
appended to it, were used in the Mascot and SequestHT searches. The resulting 
files from Proteome Discoverer were loaded into Scaffold Q+S v4.4.5 (Proteome 
Software, Inc., Portland, OR, USA). The peptide false discovery rate was 
calculated with Scaffold Local FDR algorithm, and protein probabilities were 
calculated using the Protein Prophet algorithm. Results were annotated with 
human gene ontology information from the Gene Ontology Annotations Database 
(ftp.ebi.ac.uk). 
L. Electron Microscopy—Early endosomes were precipitated on Protein G 
Dynabeads as described above. Endosome-Dynabead complexes were pelleted 
and fixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1M phosphate buffer 
(PB) overnight at 4°C. Pellets were subsequently washed in PB and fixed in 1% 
osmium tetroxide (OsO4) in PB for 90 minutes at RT. Pellets were washed in PB 
and dehydrated in an ethanol and propylene oxide series and embedded in 






and collected on nickel mesh grids. The grids were stained with uranyl acetate 
and lead citrate. Images were collected using a Hitachi HT7700 transmission 
electron microscope. Individual vesicles were measured and quantified using 
ImageJ (National Institutes of Health). The diameters of 651 endosomes were 
measured, and the corrected mean diameter (D) of all endosomes was 
calculated using the Fullman equation [D=(/2)*N/(1/d1+1/d2...1/dN)], where N 
represents the total number of compartments, and d represents the diameter of 
each individual compartment. This equation corrects for the differences in the 
positioning of the vesicles within the ultrathin sections that were cut.  
M. siRNA Knock Down of RUFY1 and PTPN23—RUFY1 siRNA (siGENOME 
SMARTpool Human RUFY1 Cat #M-016355-01, Lot #170711) and PTPN23 
siRNA (siGENOME SMARTpool Human PTPN23 Cat #M-009417-01, Lot # 
170711) were obtained from Dharmacon (Lafayette, CO). Each 5nmol stock 
siRNA was reconstituted into 20μM aliquots. Scramble control siRNA (siCON) 
was acquired from Integrated DNA Technologies (Coralville, IA). HeLa cells were 
seeded at 500,000 cells/60mm dish and transfected with final concentrations of 
50nM siRNA (or 50nM siCON) with INTERFERin (Polyplus Transfection, 
Strasbourg, France) according to manufacturer’s instructions. The following day 
(24 h post-transfection) cells were split and plated into 24-well dishes with NaOH 
washed coverslips. Seventy-two hours post-transfection, cells were serum 
starved for 2 h and then stimulated for the indicated time-points with fluorescent 







 A 6-well dish was plated for each siRNA knock-down experiment. These 
cells were harvested in RIPA buffer as previously described [63] 72-hours post-
transfection and immunoblotted for RUFY1 and PTPN23 to ensure at least 90% 
knock-down efficiency. 
N. Cell Counting—Twenty-four hours after siRNA knockdown, cells were 
plated in 35mm dishes at a density of 100,000 cells/dish. Cells were incubated 
for the indicated periods of time, and harvested using two distinct procedures. 
Immediately prior to harvest, cells were imaged at 100x magnification on a Nikon 
Eclipse Ti widefield epifluorescence microscope. To collect only viable cells, 
dishes were first washed in RT PBS. The dishes were then incubated in 250uL 
trypsin for 5 min until adherent cells were displaced. The cells were then 
collected in a final volume of 1mL in DMEM and counted using a hemocytometer 
[64]. The cells were then pelleted and harvested in RIPA buffer. To collect both 
viable and inviable cells, cells were scraped and counted using a 
hemocytometer, followed by pelleting and harvesting in RIPA buffer. Harvested 
cells were then prepared for immunoblotting. 
O. 125I-EGF Radioligand Degradation—HeLa cells transfected with the 
indicated siRNA were replated at a density of 200,000 cells/35mm dish. Seventy-
two hours after transfection, cells were incubated for 7.5 minutes in ~0.05μg/mL 
125I-EGF (0.5mL per dish, ~5000 cpm/10μL) (catalog number NEX160, 
PerkinElmer Life Sciences) at 37°C in binding buffer (DMEM, 10mM HEPES, 
0.1% bovine serum albumin, pH 7.3). Cells were washed four times in binding 






and they were returned to 37°C for the indicated periods of time. At each time 
point, the medium was collected (secreted 125I-EGF). Remaining cells were then 
solubilized in 1% NP-40, 20mM Tris, pH 7.4. Intact 125I-EGF was precipitated in 
10% trichloroacetic acid and 1% bovine serum albumin for at least 60 minutes at 
4°C. Intact 125I-EGF was separated from degraded 125I-EGF by centrifugation for 
15 min at 14,000 rpm at 4°C. Radioactivity for each fraction was counted using a 
PerkinElmer Wizard2 Gamma Counter [59]. 
P. alamarBlue Viability Assay—HeLa cells were transfected with the 
indicated siRNA and were replated 24 hours after transfection into 96-well dishes 
at a density of either 5,000 or 10,000 cells/well. When the cells reached ~50% 
confluency, they were serum starved for two hours, followed by 24-hour 
incubation with either 0, 10, or 100ng/mL EGF to induce cell growth, or with 
either 1μM AG1478 to inhibit EGFR activity or 1mM AG1478 to induce cell death. 
After incubation, alamarBlue reagent (ThermoScientific, Waltham, MA) was 
added at 10% of the total volume of media (i.e. 10μL) and incubated at 37°C and 
5% CO2 for 2 hours. Fluorescence was then measured in an HT plate reader 
using Gen5 BioTek software at 530nm excitation and 590nm emission [63]. 
Q. Inhibition of EGFR Phosphorylation via AG1478—HeLa cells transfected 
with the indicated siRNA were replated into either 96-well dishes or 35mm dishes 
24 hours after transfection. Cells were treated with the indicated concentration 
(either 1μM or 1mM) of AG1478 inhibitor (Cayman) for 24 hours prior to the 
indicated time point [65]. Cells plated in 96-well dishes were serum starved for 






using the alamarBlue assay. Cells in 35mm dishes were harvested to collect both 
viable and inviable cells. Cells were scraped and counted using a 
hemocytometer. 
R. Statistical Analyses—Unpaired student’s t-tests were used to determine 
significance. A p value of less than 0.05 is considered significant, and is denoted 
with a single asterisk (*). A p value of less than 0.001 is denoted with two 
asterisks (**). A p value of less than 0.0005 is denoted with three asterisks (***). 






















ISOLATION OF EGFR-CONTAINING EARLY ENDOSOMES 
A. Introduction 
 A multitude of labs have studied the biochemical properties of various 
endosomes, and have done so by isolating and separating endosomes from 
cells. The process of breaking open cells to separate out and study specific 
intracellular compartments is termed subcellular fractionation. Subcellular 
fractionation can be applied and modified in many ways to study the contents 
and functions of the various endocytic organelles. In this chapter, these methods 
will be outlined to determine the strengths and weaknesses of each method.  
 The process of subcellular fractionation is generally made up of three 
parts: lysing cells, separating cytosolic organelles, and isolating the target 
organelle [66]. There are several ways to perform these steps, each of which 
must also be optimized for the type of cells being used. Subcellular fractionation 
can be utilized to study virtually any organelle or compartment inside cells. 
However, the focus of this review will be on the application of these methods for 
isolating endocytic organelles. 
 The first step of subcellular fractionation involves breaking open cells to 
access internal compartments. The two major methods used to achieve this are 
hypotonic and mechanical lysis. Hypotonic lysis of cells involves incubating cells 






sucrose until enough water moves into the cells via osmosis that the cells swell 
and eventually burst. This is a very effective method for lysing cells, however, if 
the organelles are continuously exposed to a hypotonic buffer, it is possible that 
the organelles themselves risk being lysed as well. Some organelles, like 
lysosomes, are sensitive to hypotonic lysis, while others like early endosomes 
are not [67].  
The second option for lysing cells is to use mechanical disruption. This 
can be achieved by passaging cells through a syringe and a small needle 
(typically 20-25 gauge), a ball-bearing homogenizer, or exposing cells to 
sonication. All of these methods work to lyse cells by applying physical force to 
the membrane of the cell. This method is less invasive than a hypotonic buffer 
and is generally considered to have little effect on the integrity of the intracellular 
compartments. However, it has been documented that these mechanical 
techniques can cause the formation of new, non-physiologically relevant vesicles 
as a result of hybrid fusion of distinct organelles [68]. The pros and cons of both 
of these lysis methods should be considered when selecting a lysis method for 
subcellular fractionation.  
 The second step of subcellular fractionation is separating intracellular 
components. Typically after lysis, the cell lysates will be gently centrifuged to 
pellet and remove large debris and nuclei. The nuclei can be discarded or used 
for further analysis of nuclear proteins or DNA. The resulting supernatant 
contains all cytosolic organelles, proteins, cytoskeleton, and the broken plasma 






contents of the PNS must then be separated out to make the target organelle 
more accessible for the final isolation step of subcellular fractionation. The most 
common methods of organelle separation utilize centrifugation. There are two 
widely used types of centrifugation—rate zonal or differential, and isopycnic. 
Rate zonal/differential centrifugation separates samples by size, and 
isopycnic/density centrifugation separates samples by density. Creating a PNS 
from cell lysates utilizes differential centrifugation. This type of separation can 
also be used to separate any other subcellular compartments based on size. 
Generally, increasingly higher speeds are required to pellet increasingly smaller 
organelles. Large nuclei require low speeds to pellet (~600 x g), while much 
smaller mitochondria and endosomes require much higher speeds to pellet 
(~10,000-20,000 x g), and still smaller ribosomes and endoplasmic reticulum 
fragments require extremely high speeds to pellet (~100,000 x g) [66].  
Differential centrifugation is typically applied in sequence, beginning with 
low speeds to pellet large organelles and collecting the supernatant to spin at 
higher speeds to pellet smaller organelles. This process allows rapid and distinct 
separation of target compartments. However, because several organelles can 
sediment together due to size similarities, further separation methods may be 
necessary for isolation of a pure population of the target organelle. Differential 
centrifugation has been used for early/late endosome isolation [67, 69], but 
recently isopycnic centrifugation has been more commonly used. 
Isopycnic centrifugation requires the use of media to create a density 






gradient is typically created with the use of a commercially available 
heterogeneous media. During centrifugation, the media creates a spontaneous, 
self-forming gradient throughout the sample tube—the least dense materials will 
migrate to the top of the tube, and the densest materials will migrate to the 
bottom. Percoll is an example of a commonly used density gradient media for 
isopycnic centrifugation. Percoll is a mixture of colloidal silica coated with 
polyvinylpyrrolidone. When cell lysates are mixed with and centrifuged in a 
continuous gradient, organelles migrate to their isopycnic point within the 
gradient. The gradients can then be collected in multiple “fractions” to separate 
the contents with varying densities. An advantage of using a continuous gradient 
is the ability to resolve compartments with minute differences in density. 
However, a distinct disadvantage is that samples are diluted within the media, 
decreasing their concentration. This becomes more of an issue when the target 
organelle exhibits a range of densities and migrates within several fractions of 
the gradient, further decreasing their concentration. For example, early and late 
endosomes exhibit two separate ranges of densities (i.e. 1.035-1.042g/mL and 
1.048-1.070g/mL, respectively) [50]. Although this increases the range of 
fractions within the gradient that will contain these vesicles, their densities are 
distinct enough to still separate both, with minimal overlap. Percoll gradients 
have been utilized for decades to separate and isolate endosomes [70-72]. 
The second type of density gradient is a discontinuous gradient. 
Discontinuous gradients are pre-formed and made of layers of media with 






discontinuous gradient—also referred to as a “step” gradient. The final products 
of a discontinuous gradient are distinct “fractions” that can be collected from the 
“interface” between each layer of media. The number of interfaces/fractions in 
the gradient is dependent upon the number of layers in the gradient, and the 
quantity and density of the layers can be optimized based on the target 
subcellular compartment being collected. This is a distinct advantage of using a 
step gradient over a continuous gradient. The fractions from a discontinuous 
gradient can also be collected in much smaller volumes, providing more 
concentrated samples. While samples still migrate to their isopycnic point in a 
step gradient, there are a finite number of isopycnic points as they correlate to 
each distinct interface. As such, compartments collected at each fraction can 
exhibit a wide range of densities. This feature can serve as either an advantage 
or a disadvantage to this technique, depending on the target compartment. A 
disadvantage is the increased potential for samples to be contaminated with 
other subcellular organelles. Sucrose step gradients are also commonly used to 
isolate endosomes [72, 73]. 
 The third and final step of subcellular fractionation is purification of the 
target organelle. Technically, this step is not a requirement for subcellular 
fractionation. In fact, depending on the scientific question being asked, this step 
is frequently omitted altogether. In many cases, the separation and enrichment of 
target organelles with density gradients is sufficient for further study with 
biochemical techniques [59, 65]. However, obtaining a pure organelle sample is 






used for this step, and it is arguably the most important component of organelle 
isolation. Typically, in order to isolate a particular cellular compartment, a protein 
specific to the compartment of interest will be targeted. For example, antibodies 
against RAB11a, a protein specifically associated with recycling endosomes, 
were conjugated to magnetic beads, incubated with subcellular fractions, and 
placed on a magnet to purify recycling endosomes in the work of Silvis et al. [73]. 
The affinity of the antibody for its antigen, as well as the substrate to which the 
antibody is conjugated, are two critical components of this method [66]. Magnetic 
(Dynabeads), sepharose, and agarose beads are commercially available binding 
substrates with either Protein A or Protein G (or a mixture of both) coupled to the 
beads. Protein A & G are immunoglobulin-binding proteins that should be 
selected based on the source of the monoclonal antibody they will bind. The 
material make-up of the beads (Dynabeads, agarose, or sepharose) can also be 
selected based on their properties. Agarose and sepharose beads must be 
centrifuged or loaded on a column to isolate the beads and their bound 
organelles. Dynabeads, however, can be placed on a magnet and the 
supernatant removed with a pipette. Magnetic beads generally provide a gentler 
platform for isolating the target organelle, however they tend to be more 
expensive. The target organelles can be eluted off of the beads using either pH 
washes or a protein solubilizing buffer.  
Various modifications of these methods of subcellular fractionation 
detailed in this chapter were tested in order to develop a protocol optimized for 
the isolation of early endosomes from HeLa cells to study EGFR signaling from  
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these compartments.  
 
B. Results1
EGF colocalizes with EEA1-positive vesicles  
To determine the time-point at which the EGFR was maximally localized to 
the early endosome, we used indirect immunofluorescence probing for the early 
endosome marker, Early Endosome Autoantigen 1 (EEA1) [74] following 
Alexa647-EGF treatment (Figure 3.1). The addition of EGF induces a time-
dependent redistribution of EGFR into the cytosol and colocalization with EEA1. 
Fifteen minutes after the addition of EGF, there is a peak accumulation of EGF 
co-staining with EEA1. These kinetics of endocytic trafficking are consistent with 
previous reports [59, 75]. After 30 minutes of EGF treatment, there is a decrease 
in EGF and EEA1 co-staining, which is consistent with reports that the 
EGF:EGFR complex is trafficked out of the early endosome 30-60 minutes after 
EGF stimulation [76, 77]. Subsequent experiments use 15 minutes of EGF 
treatment to maximize the receptor association with the early endosome. 
 
EGFR colocalizes with early endosomal proteins in isotonic Percoll gradient 
fractions 
To biochemically enrich the early endosome population, PNS was 
prepared from HeLa cells treated without and with EGF, and separated on a 17% 
isotonic Percoll gradient [78]. Fractions of Percoll gradients were subjected to 







Figure 3.1 EGF colocalization with EEA1-positive vesicles. Serum-starved 
HeLa cells were pulse-chased with Alexa-647-EGF (10ng/mL) for 0, 5, 15, and 
30 min. Cells were fixed and processed for indirect immunofluorescence using an 
EEA1 antibody and fluorescently-labeled secondary antibody (goat anti-rabbit 
Alexa488). Scale bar=20μm. A. Images are representative of three independent 
experiments. B. The extent of colocalization between EGF or EGFR and EEA1 
was measured as described in Chapter II. Data are plotted as the percent 
colocalization for each time point (four images were taken per time point, i.e. 
each data point measured one image). Three independent experiments are 
represented with three distinct bars. Approximately 300 cells total were analyzed 
per time point per condition, per experiment. Scale bars=20μm. Images were 
quantified using ImageJ software. A Pearson’s correlation was calculated for 
each of the three experiments comparing EGF fluorescence to total EEA1 







receptor (TfnR) (early/recycling endosome marker), and late endosome/ 
lysosome associated membrane protein-2 (LAMP2) (late endosome/lysosome 
marker) (Figure 3.2A). EGFR peaked in the same fractions as EEA1 and TfnR 
(Rf ~0.25-0.10) independent of EGF treatment. The gradient distribution of 
LAMP2 indicated that there is a distinct, but not complete separation of early and 
late endosomes/lysosomes within the Percoll gradient, although a lesser amount 
of LAMP2 is present in the early endosome peak fractions. This less intense 
peak of LAMP2 increases upon EGF ligand stimulation. Phosphorylated EGFR 
(at tyrosine residue 1068, i.e. pY1068) was detected to differentiate between 
active and inactive receptors. There was a low basal level of phosphorylation in 
the unstimulated fractions, likely reflecting the population of constitutively 
recycling EGFR. These levels increased upon EGF stimulation and 
corresponded with EEA1 peak fractions.  
We also monitored the distribution of Na/K-ATPase (plasma membrane 
marker) and Calnexin (endoplasmic reticulum marker) in Percoll gradient 
fractions and found that both markers peaked in the same fractions as EEA1 and 
EGFR. These immunoblots were quantified and the relative distribution of each 
protein in the Percoll gradient was plotted (Figure 3.2B). We noticed that Na/K-
ATPase has peak concentrations in the same fractions as EEA1. This is because 
the density of plasma membrane is very close to the density of early endosomes 
(i.e. 1.045g/mL) [79]. Na/K-ATPase has also been shown to undergo endocytosis 
under certain conditions, and its presence in these fractions may also indicate 







Figure 3.2 Total and phosphorylated EGFR colocalize with early endosomal 
markers following isotonic Percoll gradient fractionation. A. PNS was 
prepared from HeLa cells treated with and without EGF (10ng/mL) for 15 min. 
PNS was resolved on a 17% isotonic Percoll gradient, fractionated, and resolved 
by 7.5% SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and 
immunoblotted for phosphorylated (pY1068) and total EGFR as well as the 
following marker proteins: EEA1 (early endosomes), TfnR (early and recycling 
endosomes), LAMP2 (late endosomes and lysosomes), Na/K-ATPase (plasma 
membrane), and Calnexin (endoplasmic reticulum). Immunoblots are 
representative of three independent experiments. B. Relative intensity of the 
immunoblots in A. Circles on the x-axis represent density bead migration (Rf 













significant enrichment of the early endosome, there is a need for additional 
endosome purification. 
 
EEA1 targeting antibodies purify early endosomes 
Due to the presence of other contaminating organelles in the EEA1 
fractions, an affinity purification strategy was used to further isolate the enriched 
early endosomes. Percoll gradient fractions with an Rf of ~0.25-0.10 (~1.04g/mL-
1.03g/mL density) were immunoisolated using an EEA1 monoclonal antibody 
(Cell Signaling) and Protein G conjugated to magnetic Dynabeads (Invitrogen). 
Magnetic beads were selected for the purification strategy to provide a rapid and 
gentle platform, as the substrate can be quickly and easily precipitated on a 
magnet. The steps of this newly developed purification strategy are outlined in 
Figure 3.3. Samples from each step of the process were collected and 
immunoblotted for multiple organelle marker proteins (Figure 3.4A). This 
strategy yielded 100% pull-down of EEA1, and approximately 7% pull-down of 
the constitutively recycled TfnR in both EGF stimulated and unstimulated 
samples. Although we expected greater pull-down of TfnR, it is not surprising as 
the constitutively recycled receptor is also localized to the plasma membrane and 
recycling endosomes. Alternatively, this low yield of TfnR could indicate that the 
early endosomes are not remaining intact throughout the isolation procedure. 
Immunoisolated fractions contained early endosome markers (e.g. EEA1 and 
TfnR) and were largely devoid of markers of other organelles (LAMP2, Na/K- 


























phosphorylated EGFR. Together, these data indicate we are successfully 
enriching EGFR-containing early endosomes. In both samples, the majority of 
phosphorylated EGFR was detected in the pass-through and not in the elution. 
This result, along with the low levels of TfnR in the elution, could also suggest 
that the early endosomes do not remain intact during isolation. However, EGF 
stimulation increases the amount of total EGFR precipitated with EEA1 more 
than 3-fold. Further, the consistent precipitation of virtually 100% of EEA1 from 
enriched gradient fractions indicates that these membrane preparations are 
highly specific for early endosomes. 
The absence of other organelle marker proteins was used as a negative 
control for early endosome precipitation. The vast majority of LAMP2, Na/K-
ATPase, and Calnexin were present in the pass-through of both samples. 
However, low but detectable amounts were present in the elutions. It is possible 
that their presence indicates contamination in the preparations. It is not likely that 
Calnexin would be found in early endosomes under normal conditions, however 
we cannot completely rule out this possibility. LAMP2 on the other hand was 
detected in the Percoll gradient early endosome fractions at low levels (see 
Figure 3.2), and because it is involved in trafficking, it is likely that its presence in 
the sample is representative of hybrid endosomes that are undergoing 
maturation [83]. Very low levels of Na/K-ATPase in the elutions indicates that 
there is minimal but detectable plasma membrane contamination. 
 







Figure 3.4 Affinity purification of early endosomes from Percoll gradient 
fractions. A. PNS from HeLa cells treated with or without EGF (10ng/mL) were 
separated on a 17% isotonic Percoll gradient. Fractions containing early 
endosome markers were immunoisolated using an EEA1 antibody as outlined in 
Chapter II. Samples were loaded by percent of total sample volume and proteins 
were resolved on a 7.5% SDS-PAGE. E=elution, PT=pass through, PF=pooled 
fractions (Percoll gradient fractions with Rf values of ~0.25-0.10), PNS=post-
nuclear supernatant. Percent of sample total is noted above each lane. 
Membranes were immunoblotted for EEA1, total EGFR, phosphoEGFR 
(pY1068), TfnR, LAMP2, Na/K-ATPase, and Calnexin. Data are representative of 
three independent experiments. B. Quantifications are shown as percentages of 
the total IP sample (i.e., elution + pass-through=100%). Data are plotted ± S.D. 
C. Electron micrograph of immunoisolated early endosomes. A representative 
micrograph of Dynabeads and early endosomes (30,000x). Scale bar=200nm. 
The diameters of 651 individual endosomes were measured using ImageJ 
software. Correcting with the Fullman equation, the mean diameter of the 
endosomes was calculated to be 68.63nm. A histogram of endosome size is 







While the biochemical data confirmed that early endosome proteins were 
being purified and other organelles excluded, we wanted to determine whether 
intact vesicles or membrane fragments were being pulled down. Early 
endosomes were enriched in Percoll gradients and affinity purified using an 
EEA1 antibody and magnetic beads. The magnetic beads-endosome complexes 
were fixed and stained for transmission electron microscopy (TEM) as outlined in 
Chapter II. The mean (± standard deviation) diameter (corrected using the 
Fullman equation) of the vesicles was 68.63 ±26.74nm (Figure 3.4C). 
TEM has been used by many investigators to visualize endosomes. Early 
endosomes appear as round structures with low density staining, while late 
endosomes stain darker and contain intraluminal vesicles. This makes the two 
endosome types easy to distinguish using TEM. The endosomes we isolated 
exhibit staining, morphology and size distribution that is indistinguishable from 
reports of early endosomes in the literature [84]. 
Mass spectrometry reveals early endosome proteins and novel EGF-dependent 
associations 
  Affinity purified endosomes were collected and subjected to liquid 
chromatography/tandem mass spectrometry as outlined in Chapter II. The 
resulting data were uploaded into a repository 
(ftp://massive.ucsd.edu/MSV000081692). Amongst all three replicates, a total of 
more than 900 distinct proteins were detected. Here, we report an abridged list of 
proteins in Figure 3.5. Multiple proteins with known associations and functions 






Figure 3.5 Early endosome and membrane trafficking proteins. Proteins 
were detected in all EGF-treated and untreated samples from three independent 
LC-MS/MS analyses of EEA1-affinity purified early endosomes. Early 
endosomes from HeLa cells treated with ±10ng/mL EGF for 15 min were 
enriched in a Percoll gradient and affinity purified using an EEA1 monoclonal 
antibody. Purified endosomes were eluted in sample buffer, resolved on a 12% 
SDS-PAGE, stained with Coomassie and subjected to LC-MS/MS as outlined in 
Chapter II. Data are compiled from 3 independent experiments and quantified 
using intensity based absolute quantification (iBAQ). A complete list of proteins 










treatment, including sorting nexins, secretory carrier-associated membrane 
proteins, EEA1, and TfnR. These data, along with the TEM images, validate the 
early endosome purification technique.  
  We also compared the protein composition of the endosomes collected 
from cells treated with and without EGF ligand. As expected, both EGF treated 
and untreated samples contain EEA1, as well as transport receptors localized to 
the early endosome (e.g. TfnR, LDLR, and IGF2R) (Figure 3.6). This 
methodology was indirectly validated by the presence of proteins involved in 
endocytosis, intracellular trafficking, membrane recycling, etc. Among the 
proteins identified, there were five that were specifically present in EGF-treated 
samples: EGFR, CCDC51, PTPN23, RUFY1, and STOML2 (Figure 3.6). Of 
these proteins, PTPN23 and RUFY1 play known roles in early endosome 
trafficking and cargo sorting [85, 86]. STOML2 is a mitochondrial protein with well 
documented roles in mitochondrial and cardiolipin biogenesis [87, 88]. CCDC51 
is a recently discovered coiled coil domain containing protein that has only been 
described based on its structure. We have used PTPN23, RUFY1, and STOML2 




In this study, we developed a novel method for enriching early 
endosomes. Immunoblotting of Percoll gradient fractions validated the separation 
of early and late endosomes using EEA1 and LAMP2 as respective marker 






Figure 3.6 Receptors detected in early endosomes and proteins that 
associate with the early endosome in an EGF-dependent manner. Early 
endosomes from HeLa cells treated with ±10ng/mL EGF for 15 min were 
enriched in a Percoll gradient and affinity purified using an EEA1 monoclonal 
antibody. Purified endosomes were eluted in sample buffer, resolved on a 12% 
SDS-PAGE, stained with Coomassie and subjected to LC-MS/MS as outlined in 
Chapter II. Data are compiled from 3 independent experiments and quantified 
using intensity based absolute quantification (iBAQ). Receptors listed (i.e. TFRC, 
IGF2R, LDLR) and EEA1 were detected in EGF treated and untreated samples 
in all three replicates. EGFR & the four novel proteins were detected in only the 
















peak fractions. While these results could be interpreted as incomplete separation 
of early and late endosomes, we propose that this lower density peak of LAMP2 
represents a population of early endosomes that are maturing into late 
endosomes. The literature supports this notion, particularly regarding EGFR 
internalization driving endosomal maturation [51]. This is supported by the 
increased intensity of the lower density LAMP2 peak after EGF stimulation. 
Further, the peak of EGFR aligns with the EEA1 peak, independent of EGF 
treatment. The presence of EGFR in these fractions without ligand stimulation 
suggests that these receptors could be present in early endosomes, plasma 
membrane, or endoplasmic reticulum membranes. For this reason, the affinity 
purification strategy was applied to the gradient enriched early endosomes. 
Biochemical and cell biological assays (TEM, immunoblotting, and mass 
spectrometry) validated the purification strategy developed in this study. These 
assays confirmed that the isolated endosomes were of the proper size and 
morphology, contained many expected resident proteins, and excluded markers 
of other organelles. TEM images also confirmed that the isolated compartments 
exhibit morphology characteristic of early endosomes. 
Despite the isolation protocol being designed to be rapid and gentle, there  
is always the possibility that the endosomes did not remain intact during isolation, 
and some associated proteins were lost. TEM was employed to test for this 
possibility (Figure 3.4C), and the data from those images suggest that the 
compartments collected were mostly intact. 





organelles, by selecting an antibody that targets an antigen with high specificity 
for the organelle of interest. LC-MS/MS provides the sensitivity and unbiased 
detection in this screen. While other labs have monitored the subcellular location 
of other trafficking and signaling proteins, they have relied primarily upon 
biochemical techniques that require a previous knowledge or predication as to 
what proteins to monitor. The process developed in this study supersedes this 
prerequisite. Using this technique, we report an EGF-dependent association of 
novel proteins with the early endosome. This protocol can be extrapolated to 
study the spatial regulation of other endocytosed receptors, including the other 
ErbB family members (i.e. Her2, ErbB3, and ErbB4), and other RTKs such as 




















THE RELATIONSHIP OF RUFY1 AND PTPN23 WITH EARLY ENDOSOMES 
A. Introduction 
 Thus far, the scope of this study has taken a very focused viewpoint on 
the protein composition of early endosomes. For the sake of simplicity and 
relevance, we have stayed within the realm of proteins that have been reported 
in the literature to play a role in EGFR trafficking and signaling. In this chapter, 
we will expand that focus to include the novel and not-so-novel proteins that we 
found to associate with EGFR in endosomes. We detected four proteins that 
associated with isolated early endosomes in an EGF-dependent manner: 
RUFY1, PTPN23, STOML2, and CCDC51. Both RUFY1 and PTPN23 have been 
previously reported to be involved in endosomal trafficking, while STOML2 and 
CCDC51 have not. This introduction will focus on what is currently known in the 
literature about the roles of these proteins in endosomal trafficking and signaling. 
Due to the lack of information on STOML2 and CCDC51 in these roles, this 
review focuses heavily on RUFY1 and PTPN23. 
 
i. RUFY1 
 RUFY1 is a RAB4 effector protein and is commonly referred to by its 
isoforms rapib4 and rabip4’. The name RUFY1 derives from its structure, as the 





proteins contain an N-terminal RUN domain that binds proteins, followed by two 
coiled-coil domains, and a C-terminal FYVE finger which binds phosphatidyl- 
inositol 3-phosphate (Figure 4.1A) [89].  
 The first work and initial discovery of the RUFY1 protein was published in 
2001 [86]. Cormont and colleagues were searching for a protein that specifically 
binds to active, GTP-bound RAB4, and thus cloned and first identified RUFY1, 
initially named rabip4 (RAB4-interacting protein) [86]. Using confocal and 
electron microscopy, they characterized rabip4 as associating with EEA1-
containing early endosomes, but not with RAB11-containing recycling 
endosomes. Their initial cloning techniques uncovered the coiled-coil domains 
and the FYVE domain of the protein, but not the RUN domain. The RUN domain 
of rabip4 was discovered and published later that same year by the same group 
[89]. They characterized the RUN domain as being responsible for tethering the 
protein to endosomal microdomains. This work also proposed that rabip4 may 
lead to sorting and recycling endosome fusion. 
In 2002, Yang and colleagues discovered what they believed to be a 
“novel” protein identical to rabip4, and coined the name RUFY1 [90]. This protein 
was discovered by screening for new effectors of the protein Etk, a tyrosine 
kinase (commonly referred to as BMX). They discovered that phosphorylation of 
RUFY1 by Etk was necessary for RUFY1 to localize to endosome membranes. In 
this study, they co-transfected B82L cells with EGFR, Etk, and various mutations 
of the FYVE domain of RUFY1 and monitored their subcellular localization via 






Figure 4.1 Secondary protein structure of RUFY1 and PTPN23. A. A 
schematic of the secondary protein structure of RUFY1. The protein consists of 
an N-terminal RUN domain, two coiled-coil domains, and a C-terminal FYVE 
domain. B. A schematic of the secondary structure of PTPN23. The protein 
consists of an N-terminal BRO-homology domain, a V-shaped homology domain, 
a histidine-rich domain, a PTP-like domain, and a proteolytic degradation 
targeting motif. Regions where STAM, K63 ubiquitin, and UBAP1 binding occur 
are also labeled. Structures were modeled after work done by Mari et al. and 













role in EGFR localization. When Etk was co-transfected with EGFR, there was a 
significant increase in the localization of EGFR to the plasma membrane of cells. 
Conversely, co-transfecting the FYVE domain of RUFY1 into these cells caused 
a reversal of the Etk-induced localization of EGFR to the cell periphery. To 
support this claim even further, they found that a mutant RUFY1 FYVE domain 
that lacked the Etk-binding site did not induce this effect. These interactions 
between RUFY1 and Etk, and between Etk and EGFR, are likely key factors that 
influence this work’s findings in RUFY1 KD cells. 
More recent studies have further elucidated the role of RUFY1 in 
endocytic trafficking. It was initially accepted that the activity of RUFY1 in 
endosomes was restricted to early and recycling endosomes. Several studies 
have shown that RUFY1 activity in the early phases of endocytic trafficking plays 
a role in periodontal disease, early onset Alzheimer’s disease, and type 2 
diabetes mellitus [92-94]. While the role of RUFY1 and its interactions with early 
endocytic RAB proteins (including RAB4, RAB5, and RAB14) have been well 
studied, it has also been shown to mediate lysosome distribution in conjunction 
with the protein AP-3 [95-97]. It is clear that all of the functions and interactions 
between RUFY1 and other proteins have not yet been uncovered, and the field of 
RUFY1 research is still in its youth.  
 
ii. PTPN23 
In 1998, a novel protein was discovered in rat cardiomyocytes called PTP-





after, the human homolog was discovered, and was coined histidine domain 
phosphotyrosine phosphatase (HD-PTP) [99]. The protein was referred to as HD-
PTP in the literature until 2009, when Gingras and colleagues discovered that the 
protein was distinct from other PTP proteins, and coined the name tyrosine-
protein phosphatase non-receptor type 23 (PTPN23) [100]. Currently, there is not 
a consensus on the name of this protein, and it is frequently referred to as both 
HD-PTP and PTPN23. For the sake of simplicity, we refer to the protein as 
PTPN23 from this point forward. 
PTPN23 has been well studied and characterized in its role as an 
endosomal protein. The major function of this protein is to sort ubiquitinated 
endocytic cargo into multivesicular bodies (MVBs) via ubiquitin binding and the 
ESCRT-I complex (Figure 4.1B). PTPN23 was first discovered about 20 years 
ago, by Cao and Zhou in 1998 [98]. They sought to discover new protein tyrosine 
phosphatases in their search to understand their role in myocardial signaling in 
rat neonatal cardiomyocytes. Cloning and expressing this protein into NIH-3T3 
cells revealed that the protein localized to “vesicle-like structures,” and inhibited 
Ha-ras-mediated transformation of these cells [98]. Two years later, researchers 
discovered that the gene for this protein was located at a specific loci on 
chromosome 3 that was frequently deleted in cancer [99]. These studies showed 
that this novel protein seems to play some sort of tumor suppressor role. 
Multiple studies in the early 2000s would corroborate the role of PTPN23 
as a tumor suppressor. It was implicated in angiogenesis and cell migration in 





group and others that the mechanism of PTPN23 activity in these processes was 
by its catalytic activity as a phosphatase. However, in 2009, Gingras and 
colleagues performed an enzymatic analysis on the protein and discovered that 
PTPN23 has neither tyrosine phosphatase nor lipid phosphatase activity [100], 
changing the way the field approached the function of PTPN23. 
The Woodman group began studying PTPN23 in relation to the protein 
Alix. The Alix protein was known to be structurally similar to the yeast protein 
Bro1p, but did exhibit the same MVB sorting activity as Bro1p [85]. In their search 
for determining the role of Alix in MVB sorting, they found that PTPN23 is a Bro1 
domain containing protein with critical implications in MVB sorting. Knocking 
down PTPN23 resulted in a 94% reduction in MVB sorting of HRP-conjugated 
EGF ligand [85]. Further studies confirmed this finding and extrapolated upon its 
mechanism. PTPN23 plays a critical role in MVB cargo sorting via interactions 
with UBPY, CHMP4B, UBAP1, SARA, and other ESCRT-0 complex proteins 
[105-107]. The mechanisms of PTPN23 cargo sorting of EGFR and other 
receptors has been and continues to be well understood. 
 
iii. CCDC51 
The protein CCDC51 was also found to associate with early endosomes in 
an EGF-dependent manner. At the current time, there have been zero studies on 
the function of CCDC51. The only known information about this protein is that it 







STOML2 has been well characterized, however, the literature seems to 
give no guidance as to the nature of the possible role of this protein in EGFR 
signaling or trafficking. The function of STOML2 has only been studied in 
mitochondria, and it is known to play important roles in mitochondrial regulation 
and biogenesis. There also seems to be some confusion in the literature as to 
the name for STOML2, as it is sometimes referred to as SLP-2. It is important to 
note that SLP-2 is sometimes used to describe a separate protein, 
synaptotagmin-like protein 2. 
In light of the discovery of an association of STOML2 with early 
endosomes, the author would like to point out that there are a few minor 
indications in the literature that could be useful guides for future research into this 
function of STOML2. First, it seems that a family member of STOML2, STOML1 
(sometimes called SLP-1), has been shown to associate with late endosomes 
[108]. Second, and even more intriguing is the well-documented but unknown 
role of STOML2 in cancers. STOML2 has been found to be overexpressed in 
multiple types of cancer, including esophageal squamous cell carcinoma 
(ESCC), glioma, and breast cancer [109-111]. STOML2 overexpression has also 
been linked to poor patient outcomes [111-113]. This presents a potential avenue 
for future studies: if STOML2 associates with early endosomes in HeLa cells, 
perhaps the mislocalization of STOML2 away from mitochondria and into 
endosomes plays a role in driving cancer cell proliferation.
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B. Results1 
Analysis of the candidate proteins and other downstream effectors in early 
endosomes 
  To determine whether these proteins associate with the early endosome in 
an EGF-dependent manner, HeLa cells were treated with and without EGF, 
prepared as a PNS, and separated over an isotonic Percoll gradient. The 
gradient fractions were immunoblotted for the candidate proteins PTPN23, 
RUFY1, and STOML2. It was expected that, as primarily early endosome-
associated proteins, RUFY1 and PTPN23 would be found in the same fractions 
in which EEA1 peaks, or those with an Rf value of ~0.25-0.10. There was a peak 
concentration of both proteins in the EEA1 peak fractions (Figure 4.2). STOML2, 
being a predominately mitochondria-associated protein, was expected to be 
found in the densest fractions, as mitochondria have a density of ~1.1g/ml. 
Interestingly, STOML2 staining was somewhat diffuse throughout the gradient 
and decreased in the EEA1 peak fractions. This suggests the possibility that 
STOML2 is not found strictly within mitochondria, and may be associated with 
other organelles of various densities. The concentration of RUFY1 appeared to 
increase in the EEA1 peak fractions upon EGF stimulation (Figure 4.2B). 
Although RUFY1 (and STOML2) appear in these fractions without EGF 
stimulation as well, this likely indicates the association of these proteins with 
other organelles in these fractions, such as plasma membrane. RUFY1 is known 
to associate with early endosomes regardless of EGFR activation, and it has also 






Figure 4.2 Immunoblot validation of candidate proteins from 
immunoisolated early endosomes. HeLa cells treated with ±10ng/mL EGF 
were subjected to Percoll gradient fractionation and EEA1-targeted 
immunoisolation as described in Chapter II. A. Percoll gradient fractions were 
resolved on a 10% SDS-PAGE and immunoblotted for EEA1, PTPN23, RUFY1, 

















endosomes [90] and can likely be found localized to both membrane populations. 
 
RUFY1, STOML2, and PTPN23 colocalize with EGF and EEA1 
 We used indirect immunofluorescence to monitor the kinetics of 
association of the candidate proteins with the early endosome. HeLa cells were 
pulse-labeled with fluorescently-labeled EGF (Alexa-647-EGF) for 0-30 minutes. 
Cells were fixed and immunostained for EEA1 and each of the candidate 
proteins. For all three proteins, there was a time-dependent association with the 
labeled EGF. This is consistent with the model of the liganded receptor 
internalizing and trafficking to the early endosome. RUFY1 and PTPN23 
colocalized with EEA1 independent of EGF treatment (Figure 4.3A and 4.3C), 
whereas STOML2 had low levels of colocalization with EEA1 that increased with 
EGF treatment (Figure 4.3B). 
 
Loss of PTPN23 or RUFY1 changes the kinetics of EGFR endocytic trafficking 
  We used RNA interference to knock down PTPN23 and RUFY1 in HeLa 
cells to determine the functional relevance of these proteins in EGFR trafficking. 
HeLa cells were transfected with 50nM siRNA or siCON (scramble control) for 72 
hours, serum starved, and treated with 10ng/mL Alexa-647-EGF ligand for 0-120-
minutes as described in Chapter II. Each experiment was repeated in triplicate, 
and a knockdown efficiency of more than 90% was achieved for each experiment 
(Figure 4.4D). 











Figure 4.3 RUFY1, STOML2, and PTPN23 colocalize with early endosomes 
and internalized EGF. A-C. HeLa cells were pulse-labeled with 10ng/mL 
AlexaFluor-647-EGF ligand (Invitrogen) for 0, 5, 10, 15, 20 and 30 minutes, 
followed by fixation in 4% paraformaldehyde. The cells were permeabilized and 
immunostained for EEA1 and either RUFY1, STOML2, or PTPN23 and 
visualized using either a goat anti-rabbit Alexa568 or goat anti-mouse Alexa-488, 
respectively. Images are representative of 0, 5, 15, and 30-minute time-points 
from three independent experiments. The extent of colocalization between EGF 
and each candidate protein or EEA1 and each candidate protein was measured 
as described in Chapter II. Data are plotted as the percent colocalization for each 
time point. Approximately 300 cells were analyzed per time point per condition, 




















Figure 4.4 EGF and EGFR colocalization with EEA1 in siCON, RUFY1 KD, 
and PTPN23 KD cells. A-C. HeLa cells were incubated with scramble control 
(siCON), RUFY1, or PTPN23 siRNA for 72 hours prior to serum starving. The 
serum starved cells were pulse-labeled with 10ng/mL AlexaFluor-647-EGF ligand 
(Invitrogen) for 0, 15, 30, 60, and 120 minutes, followed by fixation in 4% 
paraformaldehyde. The cells were permeabilized and immunostained for EEA1 
and EGFR and visualized using either a goat anti-rabbit Alexa488 or goat anti-
mouse Alexa-568, respectively. Images are representative of time-points from 
three independent experiments. The extent of colocalization between EGF or 
EGFR and EEA1 was measured as described in Chapter II. Data are plotted as 
the percent colocalization for each time point. Approximately 300 cells were 
analyzed per time point per condition, per experiment. Scale bars=20μm. Images 
were quantified using ImageJ software. D. A representative immunoblot from 
each knock-down experiment, probing for PTPN23, RUFY1, and α-tubulin. For 
each knock-down experiment, samples were loaded in multiple protein 
concentrations (20µg, 10µg, and 5µg) and the percent knockdown was 





the prolonged colocalization of EGF ligand with EEA1 at 60- and 120- minutes 
when compared to siCON (Figure 4.4A and 4.4B). A similar prolonged 
association of EGF ligand with EEA1 is also seen in the PTPN23 KD samples 
(Figure 4.4C). In addition, the loss of PTPN23 in HeLa cells also yields an 
increase in the colocalization of total EGFR with EEA1. This suggests that EGFR  
is sequestered in early endosomes after activation, and that PTPN23 plays a role  
in the endocytic progression (e.g. MVB cargo sorting or endosomal maturation) 
of the receptor. This is consistent with the results of PTPN23 KD in other labs 
[85, 107, 114]. 
 
PTPN23 loss results in slowed degradation and secretion of 125I-EGF 
 In order to further understand the roles of PTPN23 and RUFY1 in EGFR 
trafficking, we used a radiolabeled EGFR ligand (125I-EGF) and monitored its 
degradation and secretion in knock-down cell lines. RNAi was used to knock-
down PTPN23 and RUFY1 in HeLa cells, and these cells were then stimulated 
with 125I-EGF for 7.5 minutes. Unbound radioligand was washed off of the cells, 
and the dishes of cells were incubated for the various periods of time. At each 
time-point, the media was collected from each dish, which contained any 
radioligand that was secreted from the cells during the incubation process. The 
cells were then solubilized, and intact proteins were precipitated out via 
centrifugation. The supernatant contained degraded proteins that did not 
precipitate. The radioactivity in the media (secreted), pellet (intact), and 






Figure 4.5 125I-EGF radioligand trafficking in RUFY1 KD and PTPN23 KD 
cells. HeLa cells were transfected with the indicated siRNA for 72 hours prior 
to treatment. Cells were then treated with 0.05μg/mL 125I-EGF as described in 
Chapter II and incubated at 37°C for the indicated period of time. At each time-
point, the media was collected and the cells were solubilized. A. Intracellular 
degraded and B. extracellular (secreted) 125I-EGF radioactivity was counted in 
a PerkinElmer Wizard2 Gamma Counter and divided by the total radioactivity 
of each sample to calculate the percent degraded or secreted. C. Total 
radioactivity (cpm) of the collected media measured in each sample. All data 





There was a significant decrease in 125I-EGF ligand degradation in PTPN23 KD 
cells (Figure 4.5A). This result was expected, and is consistent with other 
PTPN23 KD studies in the literature. There was also a significant decrease in the 
secretion of 125I-EGF in these cells (Figure 4.5B). This supports the notion that 
there is less degradation of the ligand:receptor complex, and therefore less 
degraded ligand secreted from the cells. These data support the claim that 
PTPN23 is crucial for proper sorting of cargo into MVBs prior to lysosomal 
degradation. 
 While reviewing the raw data, we noticed that there was an increase in 
the total radioactivity in the media of the RUFY1 KD cells (Figure 4.5C). Even 
though there was not an increase in the percent of ligand secretion in the 
samples, there was still more radioactivity in all of the samples taken from 
these cells. We hypothesized that the increase in total radioactivity may be an 
artifact of an increase in total cell number of the RUFY1 KD cells. This was 
another observation we made during the propagation and experimentation 
using these cells. The RUFY1 KD cells seemed to grow more rapidly in 
comparison to siCON control HeLa cells. Next, we decided to quantify this 
change, and determine if it was EGFR-mediated.  
 
RUFY1 loss leads to a significant increase in cell number 
 In order to quantify differences in cell number due to RUFY1 and 
PTPN23 loss, HeLa cells were transfected with 50nM siRNA for 24-hours prior 






Figure 4.6 Cell number of siCON, RUFY1 KD, and PTPN23 KD HeLa cells 
under various conditions. A-C. HeLa cells were transfected with the 
indicated siRNA for the indicated time-points. Twenty-four hours after 
transfection, cells were split and plated at 100,000 cells in 35mm dishes for 
each time-point. They were then allowed to proliferate and dishes were 
harvested every twenty-four hours. Cells were harvested as indicated and as 
outlined in detail in Chapter II. Cells were counted using a hemocytometer 
after harvest. Cells treated with AG1478 were incubated with 1μM AG1478 for 






under growth conditions and cells were harvested and counted every 24-
hours. To collect viable cells, dishes were washed in PBS, trypsinized, and 
counted with a hemocytometer. There was a statistically significant increase in 
the number of viable RUFY1 KD cells as compared to siCON (Figure 4.6A).  
 In addition to counting viable cells, we also counted viable and inviable 
cells under the same experimental conditions. While monitoring the cells under a 
microscope over time, there appeared to be more dead cells floating in the media 
of dishes with PTPN23 KD and siCON cells compared to RUFY1 KD cells. For 
this reason we repeated the cell counting experiments, but adjusted the protocol 
to collect both viable and inviable cells from the dishes. 
 In order to harvest the entire population of cells on the dish, we used a cell 
scraper to harvest all of the cells in the media. The cells were counted on a 
hemocytometer, and then pelleted and resuspended in lysis buffer (see Chapter 
II). Counting the cells in this manner, we found there was still a statistically 
significant increase in the amount of RUFY1 KD cells 96 hours after transfection 
(Figure 4.6B). However, the difference between the average number of siCON 
and PTPN23 KD cells at this time-point was diminished when compared to only 
counting viable cells. This suggests that the RUFY1 KD cells grow faster than 
PTPN23 KD and siCON cells, and that there are fewer dead cells in the RUFY1 
KD dishes. 
 Next, we wanted to determine if the increased relative number of the 
RUFY1 KD cells was driven by EGFR activity. To test this, we treated cells with 





harvesting of viable and inviable cells, and in addition, treated the 72- and 96-
hour time-points with 1μM AG1478 for 24 hours prior to harvest. This 
concentration has been previously reported to be effective for attenuating EGFR 
activation [65]. Although these cells were not stimulated with any EGFR ligands, 
it was a possibility that the loss of RUFY1 KD had an effect on EGFR signaling. 
We found that AG1478 did not change the relative cell number in the RUFY1 KD 
cells 96-hours after transfection (Figure 4.6C). 
 
PTPN23 loss and treatment with AG1478 leads to membrane blebbing 
 During the cell counting experiments, we monitored the morphology of the 
cells at each time-point prior to harvest. Because there were less dead cells in 
the RUFY1 KD dishes as compared to siCON control, we wanted to visualize any 
potential morphological changes that might have been occurring in these cells. 
We noticed that there were not any obvious changes in the morphology of the 
RUFY1 KD cells (Figure 4.7B).  
 We also took images of the cells treated for 24-hours with the EGFR 
inhibitor AG1478. Although this drug did not block the enhanced growth effect in 
the RUFY1 KD cells, we did notice that, at the 96-hour time-point, there 
appeared to be membrane blebbing in the PTPN23 KD cells treated with AG1478 
(Figure 4.7C, inset). Though not quantified, this effect was seen in a multitude of 
cells on the dish, and in all three replicates of the experiment. 
 






Figure 4.7 Cell morphology of HeLa cells transfected with siCON, RUFY1, 
and PTPN23 siRNA, and treated with AG1478. HeLa cells were transfected 
with the indicated siRNA for 24-hours and replated at a density of 100,000 
cells/35mm dish. Cells were then grown for the indicated period of time and 
imaged at 100x magnification on a Nikon Eclipse Ti widefield epifluorescence 
microscope. Cells treated with an EGFR-inhibitor were incubated with 1μM 
AG1478 for 24-hours prior to imaging. Scale bar=50μm. Images are 







 Due to the decreased number of dead cells in the RUFY1 KD cells and the 
membrane blebbing seen in the PTPN23 KD cells, we wanted to determine if 
there were any changes in cell death pathways occurring in these cell lines. We 
chose to monitor PARP cleavage via immunoblotting. PARP cleavage is a  
commonly used marker for apoptosis induction. After siRNA transfection, cells  
were harvested and lysates were resolved on a 7.5% SDS-PAGE and 
immunoblotted for PARP and α-tubulin. Quantification of the immunoblots by 
Image J software showed a statistically significant decrease in PARP cleavage in 
the RUFY1 KD cells as compared to siCON control (Figure 4.8). Conversely, 
there was a significant increase in PARP cleavage in the PTPN23 KD cells 96-
hours after transfection (Figure 4.8). These results suggest that there is 
decreased apoptosis induction in RUFY1 KD cells, and increased apoptosis 
induction in PTPN23 KD cells. 
 
Cell viability in RUFY1 KD and PTPN23 KD cells under various conditions 
 Finally, we set out to corroborate these findings with another assay, this 
time monitoring cell viability using the alamarBlue assay. Due to distinct 
differences in PARP cleavage and cell number seen at the 72- and 96-hour time-
points previously, we monitored the viability of knock-down cells at both time-
points. In addition, we treated the cells with varying concentrations of EGF ligand 
or AG1478 EGFR inhibitor for 24 hours to determine if these had any effect on 






Figure 4.8 PARP-cleavage induction in RUFY1 KD and PTPN23 KD cells. 
HeLa cells were transfected with 50nM siRNA for 72- and 96-hours and 
harvested to collect viable and inviable cells (see Chapter II). A. Lysates were 
resolved on a 7.5% SDS-PAGE and immunoblotted for PARP and α-tubulin. 
Immunoblots shown are representative of the 96-hour time-point from three 
independent experiments. B. Immunoblots were quantified using Image J 
software. The mean ± the standard deviation are plotted from three independent 
experiments. PARP cleavage was calculated by dividing the quantification from 
the bottom band in the immunoblot, and dividing it by the sum of the top and 









Figure 4.9 Cell viability in siCON, RUFY1 KD, and PTPN23 KD cells under 
various conditions. HeLa cells were transfected with the indicated siRNA for 24 
hours and then plated into 96-well dishes. After 24 hours of growth, the cells 
were serum-starved for two hours, followed by 24 hours of incubation with either 
10ng/mL EGF, 100ng/mL EGF, 1μM AG1478, or 1mM AG1478. The cells were 
then incubated with alamarBlue reagent for two hours and the fluorescence was 
read on a plate reader. The average of six replicates was taken and normalized 
to the serum-starved control. The data plotted as the mean ± the standard 
deviation (n=3). A. Cell viability 72-hours after knock-down. B. Cell viability 96-





control for cell death. 
 We found that EGF ligand stimulation did not increase cell viability, but 
significantly decreased viability in PTPN23 KD cells at 72-hours (Figure 4.9A). 
1μM concentration of AG1478 also decreased cell viability in PTPN23 KD cells at 
this time-point. However, the effect was not seen at the 96-hour time-point.  
RUFY1 KD cells showed a significant increase in cell viability after treatment with 
1μM AG1478 at the 96-hour time-point (Figure 4.9B). This supports the claim 
that RUFY1 KD cells appear to have a reduced susceptibility to cell death 




The LC-MS/MS analysis of the isolated endosomes revealed that EGFR, 
PTPN23, and three previously uncharacterized proteins (i.e. STOML2, RUFY1, 
and CCDC51) associate with early endosomes in an EGF-dependent manner. 
Unfortunately, there are no antibodies commercially available for the 
uncharacterized coiled-coiled domain containing protein CCDC51, so we 
restricted further studies to RUFY1, PTPN23 and STOML2. The temporal and 
spatial association with the EGFR-containing endosomes could reflect an 
important role for these proteins in regulating EGFR signaling.  
We were struck by the absence of effector proteins among those 
associated with the early endosome (ftp://massive.ucsd.edu/MSV000081692) 





EGFR containing endosomes (e.g. Shc, Grb2, MEK2, etc.) [30, 57, 69]. As such, 
we wondered why these proteins were not detected in the mass spectrometry 
analyses. Despite LC-MS/MS being a more sensitive detection method, it does 
have limitations. As mentioned above, low-affinity associations with the 
endosomes may have dissociated during the isolation procedure. Previous work 
showing an association of these scaffold and effector proteins with early 
endosomes used immunofluorescence and immunoblotting. An alternative 
explanation is that the antibodies in those immune-detection methods generate 
an amplification of a signal, whereas LC-MS/MS quantifies only the total number 
of peptides present in a sample. As such, it is possible that the quantities of 
these and other effector proteins in the early endosomes were too low to be 
detected by LC-MS/MS; but, sufficient for detection via immunoblot and 
immunofluorescence due to signal amplification.  
RUFY1 has been previously reported to have a role in receptor tyrosine 
kinase signaling; loss of RUFY1 has been shown to inhibit PDGF-induced 
migration of fibroblasts [115]. These data support what other investigators have 
found—that RUFY1 colocalizes with EEA1 [90, 96, 115] (Figure 4.3A). PTPN23 
is the only of the four identified proteins to have been well studied in the context 
of EGFR signaling and trafficking. PTPN23 acts as a coordinator of the ESCRT 
complex pathway to transport internalized EGFR into multivesicular bodies [107, 
114]. These data support the involvement of PTPN23 in EGFR endocytic 
trafficking (Figure 4.3C). The third protein, STOML2, has been studied 





STOML2 being a driver of proliferation in multiple cancer types and is associated 
with poor patient prognosis [109-111, 116]. Yet, the mechanism of STOML2 in 
cancer cell proliferation remains unknown and the association of STOML2 with 
EGFR in early endosomes introduces some possibilities. Together, these 
findings initiate some important questions: What are the roles of these proteins in 
the early endosome? Are these proteins required for EGFR functions? Do they 
impact membrane trafficking? Do they affect EGFR signaling? 
Of the three proteins, only STOML2 increases its colocalization with EEA1 
with EGF treatment using immunofluorescence assays (Figure 4.3B). Although 
this association is modest, it is consistent with a model in which the liganded 
EGFR recruits STOML2 to the early endosome. This change in subcellular 
location could permit novel interactions that drive new, previously unknown 
functions of this protein. This is the first published result testing STOML2 
fluorescence using the specified STOML2 antibody and it is worth noting that the 
localization of the protein does not mirror what has been published using other 
STOML2 antibodies [87]. This could be due to several possibilities: 1) STOML2 
may have an abnormal distribution in HeLa cells, 2) STOML2 may be 
overexpressed in HeLa cells and a large subgroup of the proteins are 
mislocalized away from mitochondria and into endosomes, or 3) STOML2 has an 
additional association with endosomes. Another protein in the STOML2 family, 
SLP-1/STOML1, has been shown to localize to late endosomes [108], which is 
consistent with STOML2 having a role in endocytic trafficking.  





PTPN23 colocalize with EEA1 independent of EGF treatment (Figure 4.3). This 
observation contradicts the LC-MS/MS data that suggested an EGF-dependent 
association of these proteins with early endosomes. One possible explanation for 
this discrepancy is that the presence of active EGFR in early endosomes 
increased the affinity of the candidate proteins with the compartment. As such, 
the proteins may have dissociated from the endosomes during the biochemical 
isolation protocol without EGF stimulation; trafficking of the receptor to the 
endosomes stabilizes these proteins to the vesicles. 
In an attempt to further elucidate their functional role in EGFR endocytic 
trafficking, we used siRNA to knock down these proteins in HeLa cells. We 
selected RUFY1 and PTPN23 for RNA silencing, because both RUFY1 and 
PTPN23, but not STOML2, have previously reported endosomal functions. As 
such, it is more plausible that their recruitment to the early endosome would 
affect endocytic trafficking of EGFR. 
Loss of either RUFY1 or PTPN23 slowed trafficking of the EGF:EGFR 
complex and increased its colocalization with EEA1 (Figure 4.4). RUFY1 KD 
yielded sustained EGF and EEA1 colocalization. This suggests that RUFY1 loss 
slows the endocytic trafficking of the EGFR indicating RUFY1 enhances EGFR 
trafficking. RUFY1 has been reported to play a role in early endosome transport 
and recycling [86, 96] and these data support this role. PTPN23 KD yielded 
sustained colocalization of EGFR with EEA1. This suggests that PTPN23 loss 
resulted in the sequestration of the receptor in early endosomes upon EGF 





the late endosomes/lysosomal degradation. This aligns with the work of 
Woodman and colleagues, who found that PTPN23 plays a critical role in MVB 
morphogenesis and EGFR cargo sorting [85, 107]. 
We wanted to use an additional assay to monitor changes in EGFR 
trafficking upon RUFY1 and PTPN23 KD. We chose to monitor radioligand 
degradation, as these assays are extremely sensitive and highly repeatable. 
While immunofluorescence allowed us to monitor the subcellular localization of 
EGFR in the KD cells, using radio-labeled ligand allowed us to quantify changes 
in ligand:receptor complex degradation. There was a significant decrease in both 
radioligand degradation inside the cells, and secretion of ligand into the media in 
PTPN23 KD cells (Figure 4.5). This supports previous findings that PTPN23 loss 
slows EGF:EGFR trafficking to lysosomes and thus, degradation. Though the 
immunofluorescence data showed an increase in EGF colocalization with EEA1 
in RUFY1 KD cells, the radioligand assay did not show any changes in EGF 
degradation or secretion as compared to siCON control. Taken together, these 
data suggest that RUFY1 loss does not contribute to changes in EGFR 
trafficking. 
While propagating the RUFY1 KD HeLa cells, we noticed an increase in 
their growth rate. We used cell counting methods to quantify this change, and 
found a statistically significant increase in the number of RUFY1 KD cells (Figure 
4.6). Other researchers have also used RNAi to knock down RUFY1 in various 
cell lines, and have seen various effects. Vukmirica et al. knocked down RUFY1 





cells exhibited decreased migration in response to PDGF-stimulation, as well as 
a decrease in basal migration rates without ligand stimulation [115]. While 
migration and cell growth are unique processes, it is still surprising that RUFY1 
KD enhances cell growth or survival in one cell line, but stunts migration in 
another. In a separate study, Ivan et al. knocked down RUFY1 in HEK293T cells, 
and detected a 40% increase in plasma membrane protrusions as compared to 
controls [97]. We monitored the morphology of RUFY1 KD HeLa cells, but did not 
notice any changes in plasma membrane protrusions (Figure 4.7B). One 
explanation for these discrepancies is the use of different cell lines. Regardless, 
the loss of RUFY1 in HeLa cells lead to a dramatic increase in cell growth, and 
we wanted to uncover the mechanism of this effect. 
Naturally, we hypothesized that the increase in cell growth after RUFY1 
loss could have been a result of changes in EGFR activity. Although the 
trafficking of EGFR in these cells did not appear to be altered, it was possible 
that the activity of EGFR was changed in some way. Because EGFR activity is a 
known driver of cell proliferation, and we found an association of RUFY1 with 
EGFR-containing early endosomes, this seemed to be a reasonable hypothesis. 
We initially used biochemical techniques to monitor EGFR phosphorylation in the 
knock-down cell lines, but the results were inconclusive (data not shown). As 
such, we decided to use a chemical inhibitor of EGFR activity, AG1478. If EGFR 
activity was driving cell survival or growth in HeLa cells that lacked RUFY1, 
AG1478 would block this effect. However, we found that AG1478 did not 





monitored viability of the RUFY1 KD cells after being treated with AG1478 for 24 
hours, and these cells had increased viability when compared to siCON control 
treated cells (Figure 4.9B). These data strongly suggested that the increased 
cell numbers seen after RUFY1 loss in HeLa cells was not driven by EGFR 
activity.  
PTPN23 loss did not lead to the same increased relative cell number 
effect as RUFY1 loss in HeLa cells. However, we did notice that AG1478 
treatment at later time-points induced noticeable membrane blebbing in PTPN23 
KD cells, but not in other cell lines (Figure 4.7C). Membrane blebbing is 
generally attributed to the induction of apoptosis, or programmed cell death [117]. 
To quantify apoptosis induction in the KD cell lines, we monitored Poly ADP-
ribose polymerase (PARP) cleavage in each knock-down cell line. PARP is a 
family of proteins that are involved in DNA-repair. When a cell has begun the 
process of initiating apoptosis, various caspases are activated which cleave 
proteins to inhibit cell processes [117]. Caspase-3 cleaves PARP proteins, and 
the cleavage of PARP proteins can be quantified via immunoblotting. We found 
that, over time, PTPN23 KD cells had increased PARP cleavage (Figure 4.8). 
This effect was not monitored after AG1478 treatment, but was seen in untreated 
PTPN23 KD cells. In addition, we monitored the viability of these cells after 
treatment with EGF ligand or AG1478 and found that all treatments significantly 
reduced cell viability of PTPN23 KD cells at the 72-hour time-point (Figure 4.9A). 





death induction. The mechanism of this effect is unknown, and future studies are 



























SUMMARY AND FUTURE DIRECTIONS 
A. Restatement of Research Goals 
 The goal of this dissertation work was to better understand the 
implications of EGFR spatial regulation on its interactions with downstream 
signaling proteins. While EGFR trafficking is well understood, there is currently 
no consensus in the field as to how endocytic trafficking spatially regulates EGFR 
signaling. Identifying proteins that are recruited to early endosomes in an EGF-
dependent manner not only provides a platform for further study on mechanisms 
and outcomes, it also provides a means for finding new potential targets for 
mediating EGFR signaling cascades. 
 
B. Summary of Findings 
 We have developed a rapid and reproducible technique to isolate early 
endosomes from cultured cells. Biochemical techniques were used to validate 
the isolation of a pure population of early endosomes with virtually no 
contamination from other organelles. Morphological studies revealed that the 
isolated vesicles had similar characteristics to early endosomes.  
In addition to developing this isolation technique, we used it to analyze the 
proteome of early endosomes. We have identified four proteins associating with 





and STOML2 [118]. Other studies have reported an association of RUFY1 and 
PTPN23 with early endosomes [85, 86]. However, this is the first report of either 
CCDC51 or STOML2 associating with early endosomes. We validated the 
association of RUFY1, PTPN23, and STOML2 with early endosomes using 
indirect immunofluorescence and immunoblotting.  
Knock-down studies were utilized to determine the roles that RUFY1 and 
PTPN23 played in EGFR trafficking. Immunofluorescence revealed that the loss 
of PTPN23 lead to a prolonged association of EGFR with EEA1, a marker for 
early endosomes. Radioligand binding studies confirmed this phenomenon. This 
finding is consistent with the literature and supports the claim that PTPN23 is an 
important component of cargo sorting from late endosomes to lysosomes for 
degradation. 
Though these knock-down studies did not reveal any changes in EGFR 
trafficking due to RUFY1 KD, we did notice that these cells had a dramatically 
increase number of cells. To quantify this, we counted cells and found a 
significant increase in the number of RUFY1 KD cells when compared to siCON 
cells plated at the same density. While other reports have knocked down RUFY1 
in various cell lines, we are the first to report this characteristic.  
We wanted to determine if the increased number of RUFY1 KD cells was 
driven by EGFR activity. A chemical inhibitor of the EGFR kinase, AG1478, was 
used to block EGFR activity while monitoring cell number. These studies did not 
reveal any change in RUFY1 KD cell number−however, monitoring the 





caused membrane blebbing in the PTPN23 KD cells. This suggests that loss of 
PTPN23 may increase susceptibility to cell death processes. 
To quantify the induction of apoptosis in each cell line, PARP cleavage 
was calculated using immunoblotting. These studies revealed that RUFY1 KD 
cells had a significant reduction in PARP cleavage as compared to siCON cells, 
suggesting loss of RUFY1 caused increased cellular stress tolerance. In addition, 
we found that PTPN23 KD induced an increase in PARP cleavage. This result 
corroborated the morphological images showing membrane blebbing in PTPN23 
KD cells after AG1478 treatment. While the loss of RUFY1 seems to enhance 
cell survival, the loss of PTPN23 seems to have the opposite effect. 
Finally, we used the alamarBlue assay to quantify cell viability in each 
knock-down cell line. These studies supported the hypothesis that RUFY1 KD 
cells had increased viability under stressful conditions, and PTPN23 KD cells had 
decreased viability overall. Future studies will be critical in determining the 
underlying mechanisms for these findings. 
 
C. Significance of Findings 
 The endosome isolation technique developed here could be utilized by 
many areas of research. This technique can be applied to the study of numerous 
proteins, receptors, kinases, and signaling effectors. For researchers interested 
in other organelles, this technique can be modified by changing what Percoll 
fractions are collected and what antigen is targeted during the affinity purification 





further research are vast.  
 Aside from the development of the isolation technique, the discovery of an 
association of CCDC51 and STOML2 with early endosomes is completely novel. 
Neither of these proteins has been previously reported to associate with either 
EGFR or early endosomes. This provides a platform for numerous future studies 
to elucidate the mechanisms of these interactions. In addition, virtually nothing is 
known about the function of the protein CCDC51. The finding that CCDC51 
associates with EGFR and early endosomes could provide some insights into the 
roles of this protein. 
 We have also found that RUFY1 loss leads to enhanced survival. To the 
author’s knowledge, this is the first report of its kind. Until now, RUFY1 has been 
studied exclusively for its roles in endocytic trafficking. The mechanism for the 
enhanced survival activity of RUFY1 is currently unknown. 
 The findings reported within this dissertation are significant for several 
reasons. First, the early endosome technique developed herein can be used to 
study myriad endocytic proteins, including other receptors that are endocytosed. 
The isolation technique can also be modified to isolate other intracellular 
organelles. Second, we have discovered novel associations of both CCDC51 and 
STOML2 with both EGFR and early endosomes. Finally, we have discovered a 
potential role for RUFY1 as driver of cell survival or cell growth. These 
discoveries will drive multiple fields forward toward better understanding of 
organelles, receptor trafficking, and CCDC51, STOML2, and RUFY1 functions. 






A major strength of this work is in its use of HeLa cells. This cell line 
expresses EGFR at levels similar to what has been measured in normal human 
epithelial tissues (~50,000 EGFRs per cell), allowing us to correlate findings in 
these cells with the physiologic activity of EGFR. To this same end, physiologic/   
low levels of EGF ligand were used to stimulate EGFR activation (10ng/mL). Low 
concentrations of EGF ligand limit endocytosis of EGFR to the clathrin-mediated 
type, which is the type of endocytosis that occurs in normal physiology. Further, 
HeLa cells grow rapidly, permitting the generation of large populations of cells, 
which was required for subsequent endosome enrichment.   
We were able to isolate early endosomes without introducing exogenous 
factors into the cells. While it is generally acceptable to use cell lines that have 
been genetically altered to enhance detection and capture of the target protein of 
interest, we were able to enrich early endosomes without the use of epitope 
tagged proteins or transfection reagents. As a result of this, the isolated early 
endosomes are physiologically relevant. The proteomics data obtained from 
these compartments can thus be taken at face value, without concerns about 
non-physiologic changes in their structure or function. 
The proteomics method used in these studies is also a strength of this 
work, because LC-MS/MS is a highly sensitive and robust technique. In addition, 
it provides researchers with an unbiased platform for analyzing the protein 
composition of a sample. Other techniques require a prerequisite knowledge 





specific protein, EEA1, and assess the entire proteome of the compartments 
isolated with this antigen. This approach uncovered a large amount of data from 
in vitro samples that were reproducible. 
 
ii. Weaknesses 
One of the few limitations of this work is that it was performed using 
cultured cells.  A major drawback to using tissue culture rather than animals is 
that the results cannot be correlated to the organism level.  Cultured monolayers 
of cells lack the complex interplay of signaling that occurs within organisms and 
even tissues.  Tissue culture models are ideal for preliminary studies, however, 
isolating early endosomes from an animal would provide a more physiologically 
relevant analysis of EGFR signaling from these compartments.  
Another weakness of this work is that all experiments were conducted 
using HeLa cells. Although this cell line is useful and extremely common, it is 
important to remember that these cells are a human cervical adenocarcinoma 
line. Cancer cells tend to behave and function in different ways from non-
transformed cells, and there may be changes in signaling pathways in this cell 
line for which we have not accounted. For this reason, it is crucial that this work 
be repeated in other cell lines to validate that the findings reported herein are not 
specific to HeLa cells. 
 
E. Future Directions 





future research. We have uncovered novel associations of STOML2 and  
CCDC51 with early endosomes and EGFR. Because this is the first report of 
these associations for either protein, future work is needed to understand the 
roles these proteins play in endocytic trafficking and potentially EGFR signaling. 
Although there are currently no commercially available antibodies for CCDC51, 
the production of these would be critical to study the subcellular localization and 
functions of this protein. STOML2 KD studies would also be a useful start to 
determining the role of STOML2 in EGFR trafficking and signaling. 
While we began studying RUFY1 in the context of EGFR trafficking and 
signaling, more work is needed to determine the exact role of RUFY1 in this 
regard, as well as to uncover the newly discovered survival role of RUFY1. One 
protein that may serve as an intermediate to these processes is Etk, also known 
as BMX. As discussed briefly in Chapter IV, one group found that Etk is required 
for proper early endosome localization of RUFY1 by phosphorylating the RUFY1 
coiled-coil domains [90]. Their data suggested that Etk plays a role in the plasma 
membrane localization of EGFR, which was reversed upon introduction of the 
RUFY1 FYVE domain into cells. They concluded there is an interplay between 
Etk, RUFY1, and EGFR.  
The interplay of Etk, RUFY1, and EGFR provides a novel perspective for 
the research presented in this dissertation, particularly in regard to the increased 
cell number effect that is induced upon loss of RUFY1. For example, if Etk 
enhances plasma membrane localization of EGFR, and RUFY1 inhibits this 





EGFR plasma membrane localization. The Yang group also found that the 
enhanced localization of EGFR at the plasma membrane by Etk caused an 
increase in MAPK activity after EGF stimulation [90]. They hypothesized that the 
tyrosine kinase Etk is downstream of the signaling protein PI3K. If this is true, 
then RUFY1 acts as a negative regulator of PI3K activity by inhibiting some of 
the activities of Etk, which supports the finding in this dissertation that RUFY1 
enhances cell survival. The inverse of this would be that loss of RUFY1 permits 
uninhibited Etk activity. This would explain why blocking EGFR activity did not 
reverse the increased cell number effect seen in RUFY1 KD cells. Although PI3K 
is technically downstream of EGFR, if Etk is downstream of PI3K, then removing 
an Etk inhibitor would permit Etk activity without EGFR activation. However, this 
would require the activity of some other Etk-activating protein, be it PI3K or 
another protein (Figure 5.1). Elucidating the relationships between Etk, EGFR, 
and RUFY1 will likely be critical in uncovering how RUFY1 acts as a driver of cell 
growth or survival. 
There are numerous publications demonstrating that Etk has oncogenic 
activity. Several clinical groups have shown that Etk overexpression drives 
cancer cell proliferation and chemoresistance, and that loss of Etk diminishes 
these effects [119-122]. These claims support the hypothesis that if RUFY1 does 
in fact inhibit Etk activity, then RUFY1 has enhanced cell survival or growth 
effects. Yang and colleagues reported that there are two potential binding sites 
for RUFY1 and Etk to interact with one another [90]. This supports the notion of 






Figure 5.1 A schematic representation of a signaling pathway permitting 













studies will be crucial in validating this finding and determining any other effects 
induced by RUFY1 and Etk interactions. 
One study that will be critical for testing the enhanced cell survival 
activities of RUFY1 is to measure Etk activity in RUFY1 KD cells. If Etk activity is 
enhanced after RUFY1 loss, then this should be easily measured using 
biochemical techniques. It is possible that Etk phosphorylation is not increased, 
but instead the loss of RUFY1 may permit additional interactions of Etk with other 
proteins. It will be important to determine not only where RUFY1 and Etk are 
binding but how this interaction changes the activity of Etk, be it structurally or 
catalytically. One means to measure this would be to isolate the two proteins and 
visualize their interaction using X-ray crystallography. Mutating various sites on 
both proteins and creating dominant negative mutants will also be a useful 
means for determining what domains of the proteins are interacting and how 
each domain affects the function of each protein. However, the enhanced 
survival activity of RUFY1 may be independent of Etk activity. Testing this would 
require a simple experiment where both RUFY1 and Etk are knocked down in 
HeLa cells. If loss of Etk inhibits the enhanced growth of RUFY1 KD cells, then 
Etk is very likely to be the driver of cell growth upon RUFY1 loss. If Etk loss does 
not inhibit this effect, then there is some other process mediating the increased 
survival of RUFY1 KD cells that would need to be further explored. It is also 
possible that Etk KD introduces additional effects to the cells. Etk KD alone in 
HeLa cells should also be tested to determine how Etk loss affects HeLa cell 





synergistic effect on enhancing cell growth or survival. These studies will be 
important for understanding the relationship between Etk and RUFY1. 
Another caveat of RUFY1 and Etk interactions is that Etk phosphorylation 
of RUFY1 is required for early endosomal localization of RUFY1 [90]. This role 
could also be due to Etk being downstream of PI3K and could explain why we 
detected an EGF-dependent localization of RUFY1 with early endosomes in 
Chapter III. In other words, EGFR activation induces activation of the PI3K 
pathway, including Etk, which phosphorylates RUFY1 and induces its localization 
to early endosomes. However, as addressed in Chapter IV, other reports have 
shown that RUFY1 is predominantly localized to early endosomes [95]. One 
means for determining the role of Etk in RUFY1 localization is to knock down Etk 
and monitor the localization of RUFY1 using immunofluorescence. This would 
determine if Etk is necessary for RUFY1 localization to early endosomes. This is 
another important aspect of the relationship between Etk and RUFY1 that needs 
to be elucidated to better understand their functions in endocytic trafficking. 
Though not exhaustive, we have presented multiple avenues for future 
work that will be critical for expanding upon the findings of this dissertation. The 
functional role of CCDC51 has yet to be determined, in regard to early 
endosomal trafficking and otherwise. The mitochondrial protein STOML2 has 
unknown roles in EGFR trafficking and signaling as well as cancer cell 
proliferation that have yet to be elucidated. Finally, the survival effect of RUFY1 
reported herein is the first of its kind. The mechanism behind this effect could be 





proposed that will be critical in determining the role of Etk in this phenomenon, as 
well as the role of Etk on EGFR trafficking.  
The original goal of this research was focused on elucidating the effects of 
spatial regulation on EGFR signaling. In the process of pursuing this question, 
we have uncovered several new proteins as effectors of EGFR in early 
endosomes. While several new avenues of research have been presented that 
could drive entirely novel fields of work, these proteins may also be important 
drivers in EGFR trafficking and signaling. Future work that is focused on 
uncovering the roles of these proteins in this manner will be crucial factors in 
driving the field’s understanding of EGFR spatial regulation, endocytic trafficking, 
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